



4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases

This is the peer reviewed version of the following article:

Original:

Santucci, A., Bernardini, G., Braconi, D., Petricci, E., Manetti, F. (2017). 4-Hydroxyphenylpyruvate Dioxygenase and Its Inhibition in Plants and Animals: Small Molecules as Herbicides and Agents for the Treatment of Human Inherited Diseases. JOURNAL OF MEDICINAL CHEMISTRY, 60(10), 4101-4125 [10.1021/acs.jmedchem.6b01395].

Availability:

This version is available <http://hdl.handle.net/11365/1006035> since 2017-07-31T11:22:42Z

Published:

DOI: <http://doi.org/10.1021/acs.jmedchem.6b01395>

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

4-Hydroxyphenylpyruvate dioxygenase and its inhibition in plants and animals: small molecules as herbicides and agents for the treatment of human inherited diseases

Journal:	<i>Journal of Medicinal Chemistry</i>
Manuscript ID	jm-2016-01395k.R4
Manuscript Type:	Perspective
Date Submitted by the Author:	n/a
Complete List of Authors:	Santucci, Annalisa; University of Siena, Italy, 1. Università degli Studi di Siena, Dipartimento di Biotecnologie, Chimica e Farmacia Bernardini, Giulia; University of Siena, Department of Molecular Biology Braconi, Daniela; Università degli Studi di Siena, Dipartimento di Biotecnologie Petricci, Elena; University of Siena, 1. Università degli Studi di Siena, Dipartimento di Biotecnologie, Chimica e Farmacia Manetti, Fabrizio; Università degli Studi di Siena, Dipartimento di Biotecnologie, Chimica e Farmacia

SCHOLARONE™
Manuscripts

1
2
3 **4-Hydroxyphenylpyruvate dioxygenase and its inhibition in plants and animals: small**
4 **molecules as herbicides and agents for the treatment of human inherited diseases**
5
6
7
8
9

10 Annalisa Santucci, Giulia Bernardini, Daniela Braconi, Elena Petricci, Fabrizio Manetti*

11 *Dipartimento di Biotecnologie, Chimica e Farmacia, via A. Moro 2, I-53100 Siena, Italy. Phone:*

12 *+39 0577 234330, Fax: +39 0577 234254, email: fabrizio.manetti@unisi.it*
13
14
15
16
17
18
19

20 **Abstract:** This review mainly focuses on the physiological function of 4-hydroxyphenylpyruvate
21 dioxygenase (HPPD), as well as on the development and application of HPPD inhibitors of
22 several structural classes. Among them, one illustrative example is represented by compounds
23 belonging to the class of triketone compounds. They were discovered by serendipitous
24 observations on weed growth and were developed as bleaching herbicides. Informed reasoning on
25 nitisinone (NTBC, **14**), a triketone that failed to reach the final steps of the herbicidal design and
26 development process, allowed it to become a curative agent for type I tyrosinemia (T1T), and to
27 enter clinical trials for alkaptonuria. These results boosted the research of new compounds able to
28 interfere with HPPD activity to be used for the treatment of the tyrosine metabolism-related
29 diseases.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

4-Hydroxyphenylpyruvate dioxygenase (HPPD) is an iron-dependent non-heme oxygenase involved in the catabolic pathway of tyrosine (Tyr), with very different roles in prokaryote organisms, plants, and animals. In the last four decades, a significant number of HPPD modulators has been discovered in the field of agrochemicals for weed control. In this context, an in deep analysis of the HPPD inhibitor activity and mechanism of action led to recycle a triketone compound originally designed as herbicide as a drug for the cure of human T1T.¹

Drug repositioning (also known as redirecting, repurposing, and reprofiling),^{2,3} which is the identification and development of new uses for existing drugs, has been widely applied within the drug development process.⁴ In most cases, it was based on pure serendipity (one classic success story is represented by sildenafil, initially studied as an anti-angina agent and currently used to treat erectile dysfunction), while in a limited number of cases it was the consequence of an informed reasoning.^{5,6}

Drug repositioning is currently a widespread approach often described in the most recent scientific literature.^{3,7} It was adopted by important research centres^{8,9} and the main driver for establishing novel companies,¹⁰ journals,¹¹ and conferences¹² specifically addressing this topic. As a striking example, a recent paper describing the use of molecular modeling and docking simulations for repositioning 2,4-dichlorophenoxy acetic acid (a plant hormone belonging to the auxin class) as a potential anti-inflammatory agent able to inhibit the COX-2 enzyme can be cited.¹³

One of the compounds reviewed in this paper represents a classic example of reasoned repurposing of an active ingredient. This examples dates back to the eighties, well before coining of the concept of “drug repositioning”. In those years, triketones were identified as corn-selective

1
2
3 herbicides. Further investigations of such compounds in terms of toxicology and mechanism of
4
5 action allowed HPPD (the second enzyme involved in the Tyr metabolism pathway, Figure 1) to
6
7 be identified as the molecular target.¹⁴ Based on the ability of triketones to block HPPD, a
8
9 brilliant intuition arose to use 2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
10
11 (nitisinone, NTBC, **14**, a triketone, Figure 10) to treat T1T,¹ a fatal disease caused by inactivity
12
13 of the fumarylacetoacetate hydrolase (FAH, an enzyme downstream of HPPD itself, Figure 1).¹⁵
14
15 Since the disease is characterized by the accumulation of toxic metabolites as a consequence of
16
17 FAH dysfunction (Figure 28), the upstream blocking of HPPD avoids the production of such
18
19 toxic metabolites.
20
21
22
23

24
25 Besides its use in T1T, **14** recently accessed clinical trials for alkaptonuria (see below), a disease
26
27 due to dysfunction of homogentisate dioxygenase (HGD, another enzyme within the Tyr
28
29 metabolic pathway, Figure 1). In this case, inactivity of HGD results in accumulation of 2,5-
30
31 dihydroxyphenylacetic acid (homogentisic acid, HGA, **2**, an intermediate of the pathway) that
32
33 undergoes oxidation and polymerization (Figure 9), fixation on cartilages and other tissues, with
34
35 consequent invalidating outcomes.¹⁶ By inhibiting HPPD, **2** cannot be further accumulated in
36
37 alkaptonuria patients treated with **14**.
38
39

40
41 Finally, **14** could be potentially used in hawkinsinuria, a disease where HPPD mutations cause
42
43 the production of hawkinsin (Figure 7), an unusual amino acid that is responsible for disease
44
45 symptomatology.
46
47

48
49 All of the above considerations show that relocation of **14** from the agrochemical to the medical
50
51 field can be considered a unique case of drug repositioning: a single drug targeting a specific
52
53 enzyme could be now used to treat two (T1T and alkaptonuria) or perhaps three (if hawkinsinuria
54
55 is included) human diseases.
56
57
58
59
60

1
2
3 The important role played by triketones and structurally different HPPD inhibitors led many
4
5 research groups from both academy and pharmaceutical/agrochemical companies to design,
6
7 synthesize, and test many additional compounds to find new modulators of HPPD activity. The
8
9 aim of the present review is to describe such efforts. In particular, structural and functional
10
11 properties of HPPD as well as the involvement of the enzyme in human diseases are described in
12
13 the first paragraphs. Then, a literature survey is presented to summarize and describe the various
14
15 classes of compounds able to interfere with HPPD activity, providing structural requirements and
16
17 pharmacokinetics parameters.
18
19
20
21
22
23

24 25 **2. The enzymatic pathway**

26
27 Since its discovery, HPPD has been gaining crucial importance due to its involvement both in
28
29 human hereditary diseases and biosynthesis of UV shields necessary for chlorophyll protection in
30
31 plants.
32
33

34 In humans, HPPD is a key enzyme within the catabolic pathway Tyr that begins with the
35
36 hydroxylation of natural phenylalanine (Phe) and proceeds with its degradation to small anionic
37
38 species, such as acetoacetate and fumarate (Figure 1). During the first step, Phe is hydroxylated at
39
40 the *para*-position by the Fe(II)-dependent phenylalanine-4-hydroxylase (PAH) in the presence of
41
42 oxygen and tetrahydrobiopterin as cofactor to yield Tyr. In the next step, a reversible reaction
43
44 catalyzed by the Tyr aminotransferase (TAT, a transaminase) converts Tyr into 4-
45
46 hydroxyphenylpyruvate (HPP, **1**), in the presence of 2-oxoglutarate as co-substrate and pyridoxal
47
48 5'-phosphate as cofactor. Compound **1** is then transformed into **2** by HPPD. An additional iron-
49
50 dependent dioxygenase (HGD) is responsible for the ring-opening reaction to 4-
51
52 maleylacetoacetate, which then undergoes a *cis-trans* reversible isomerization, catalyzed by the
53
54
55
56
57
58
59
60

1
2
3 glutathione-dependent maleylacetoacetate isomerase (MAAI), to yield 4-fumarylacetoacetate. In
4
5 the last step of the pathway, fumarylacetoacetate is hydrolyzed into acetoacetate and fumarate by
6
7 FAH, a Ca/Mg-dependent hydrolase.
8
9

10 11 12 **3. The enzyme HPPD**

13
14
15 HPPD (EC 1.13.11.27) belongs to the class of α -keto acid-dependent oxygenases that have only
16
17 two substrates: **1** (either as the source of α -keto acid or the small molecule where the reactions of
18
19 the catalytic cycle occur) and molecular oxygen. They differ from the majority of α -keto acid-
20
21 dependent oxygenases that requires α -ketoglutarate as the source of α -keto acid and an additional
22
23 substrate to be processed, in addition to oxygen molecules.^{17,18}
24
25
26

27 28 *3.1. Human HPPD: isoforms and mutations*

29
30 HPPD is an oxidoreductase with dioxygenase activity that catalyzes the third step of the catabolic
31
32 pathway of Phe and Tyr, consisting in the oxidation of **1** to **2**. In humans, HPPD is characterized
33
34 by a 393 amino acid sequence (entry P32754¹⁹ of the UniProt Knowledgebase database -
35
36 UniProtKB/Swiss-Prot).²⁰ Two isoforms produced by alternative splicing have been described:
37
38 the full length isoform 1 (392 amino acids, missing Met1; numbers are according to the 393
39
40 amino acid sequence P32754¹⁹ of the human HPPD) and the truncated isoform 2 with the
41
42 sequence 1-39 of missing residues. At least 5 modified amino acids have been described: three
43
44 phosphoserines (211, 226, and 250), one *N*6-succinyllysine (132), and an *N*-acetylthreonine (2).
45
46
47 Natural variants involved in type III tyrosinemia (namely, Ala33Thr, Tyr160C, Ile267Phe,
48
49 Ala268V, Ile335Met, and Val340Leu), hawkinsinuria (namely, Ala33Thr, Asn241Ser, and
50
51 Ala268V), or not yet correlated to any disease (namely, Arg113Gln), have been described. A
52
53 metal binding site containing an iron ion as the cofactor is constituted by His183, His266, and
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Glu349. The last amino acid is critical for catalytic activity of HPPD. In fact, while metal coordination could be guaranteed by the two His residues, variants at the Glu349 residue only show a 5-10% residual activity at maximum.²¹

3.2. Multiple sequence alignment

Among about half a million sequences of the reviewed section of the UniProtKB/Swiss-Prot, 28 sequences (Table 1) have been described as belonging to the HPPD enzyme. Multiple sequence alignment performed on them with Clustal Omega at the Protein Information Resource (PIR) web site²² showed that 18 out of the 44 (41%) conserved amino acid residues are contouring the Fe(II) binding site (Supporting Information, Table S1): Asp182, His183 (catalytic triad), Gln265, His266 (catalytic triad), Ala268, Leu332, Leu333, Gln334, Phe336, Phe347, Glu349 (catalytic triad), Ile351, Gly358, Phe359, Gly360, Gly362, Asn363, Phe364. This suggests a high structural similarity among the iron-containing HPPD binding sites from various sources.

3.3. Three-dimensional structures of holo-HPPD and HPPD-inhibitor complexes

Despite the high structural similarity showed at the level of the binding site, HPPDs from various organisms differ for their oligomeric state. In fact, HPPD from mammals,²³ plants,²⁴ and *Streptomyces avermitilis*²⁵ are homodimers, while the *Pseudomonas fluorescens* HPPD (*Pf*HPPD) is organized in homotetramers.²⁶ Moreover, the monomer surfaces responsible for the formation of dimers and tetramers are different in plant and bacterial enzymes.²⁴ Significant differences have been also found at the level of single monomers. As an example, the C-terminal α -helix H11 of *Zea mais* HPPD (*Zm*HPPD) is interposed between the solvent and the active site, while a 60 degrees rotation of the same helix exposed the *Arabidopsis thaliana* HPPD (*At*HPPD) binding site to the solvent.²⁴ A similar conformational rearrangement of the C-terminal α -helix

1
2
3 (namely, a rotation of about 40 degrees) was found in the complex between *Streptomyces*
4 *avermitilis* HPPD (*Sa*HPPD) and **14**, in comparison to the *Pf*HPPD.²⁵

5
6
7
8 The Protein Data Bank (RCSB PDB)²⁷ collects 12 3D structure of HPPD from different
9 organisms (prokaryotes, plants, and mammals, Table 2). All of them have been determined by X-
10 ray crystallographic studies and showed a different coordination sphere of their iron cofactor. Six
11 of the PDB entries describe HPPD in its holoenzymatic form. Unfortunately, the structure of the
12 complex between HPPD and its natural substrate **1** or one of its reaction intermediates and
13 transition states is not available yet neither from experimental sources nor from theoretical
14 calculations. However, the 3D structures of six complexes between HPPD and small molecule
15 inhibitors are available which contain a pyrazole [(namely, **3** (DAS869),²⁸ and **4** (DAS645),²³
16 Figure 2)] or a triketone (namely, **14** and sulcotrione **15**, Figure 10) inhibitor (Table 2). None of
17 them is from a human source.

31 32 3.4. HPPD-inhibitor interactions

33
34 An analysis of the graphical representation of the co-crystallized HPPD-inhibitor complexes
35 provides a detailed description of the interaction pattern between the inhibitor and the HPPD
36 binding site. The C-terminal domain of the enzyme (Gln375 seems to be critical in humans)²⁹
37 harbor a wide cavity exposed to the solvent that accommodates the iron ion cofactor. Iron
38 coordination is fulfilled by the usual amino acids (two His and a Glu), while the remaining
39 coordinating water molecules are replaced by the β -keto-enol system found either in the pyrazole
40 and triketone inhibitors. While both **14**³⁰ and the diketone nitrile of isoxaflutole (**24**, Figure 11)³¹
41 were described to bind the complex between HPPD and ferrous ion, within the co-crystal
42 structure between HPPD and pyrazole inhibitors neither the metal ion at the binding site (iron or
43 cobalt) nor its oxidation state (+2 or +3) can be distinguished.²³ On the contrary, X-ray
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 crystallography confirmed that **14** binds to the ferrous/HPPD system,²⁵ while the cofactor of the
4
5 HPPD-**15** complex is reported in its ferric form (Table 2).
6
7

8 3.5. Comparison of the complexes between the pyrazole **3** and HPPD from different organisms

9
10 A superposition was performed by the Superimpose Proteins tool (provided by the Discovery
11
12 Studio 3.0 Visualizer software)³² between the two complexes (namely, 1SQI from *Rattus*
13
14 *norvegicus* and 1TFZ from *Arabidopsis thaliana*) containing the same pyrazole inhibitor **3**
15
16 (Figure 3). A very similar binding mode of the inhibitor was found (308 residues with a 1.2 Å
17
18 root mean square deviation, rmsd, on C α atoms), consequent to the fact that all of the amino
19
20 acids in the binding site were conserved residues, although the entire sequences showed only a
21
22 29% amino acid identity. In particular, apart the interactions that involve the β -keto-enol system
23
24 of the pyrazole ring, additional complex stability arose from various π - π interactions involving
25
26 the aromatic portion of Phe residues and the phenyl rings of the inhibitor. Hydrophobic contacts
27
28 were also found between the N-*t*Bu group of the inhibitor and a Pro residue. Unexpectedly, no
29
30 hydrogen bonds and ionic interactions involving the inhibitor were found for complex
31
32 stabilization.
33
34
35
36
37
38

39 3.6. Comparison of the complexes between AtHPPD and different pyrazole inhibitors

40
41 An expected better superposition (362 residues with a 0.3 Å rmsd, Figure 4) was found between
42
43 two structures from *A. thaliana* (namely, 1TFZ and 1TG5) with different pyrazole inhibitors
44
45 (namely, **3** and **4**). The usual interactions with the iron ion and with the aromatic portions of the
46
47 inhibitor were maintained, without any hydrogen bond. The major difference was due to the 115
48
49 degrees rotation of the Phe403 side chain induced by the presence of the 2,4-dichlorophenyl
50
51 group of **4**. Such a conformational rearrangement, together with a significant displacement of a
52
53 Pro residue and to the flexibility of the C-terminal helix, accounted for the 12 nM inhibitory
54
55
56
57
58
59
60

1
2
3 activity of **4** toward *At*HPPD, and for the inability of the same compound to inhibit the rat
4 enzyme that can not undergo these structural changes.²³ Compound **4** has been discovered within
5 a campaign for the identification of plant-selective HPPD inhibitors, starting from a small
6 database (about 1000 entries of the Dow AgroSciences library) of HPPD inhibitors. Selectivity of
7 such a compound was attributed to the presence of its N1-*t*Bu and C3-phenyl substituents which
8 were identified as common structural features for plant selectivity. These chemical groups induce
9 the Pro displacement and the Phe conformational rearrangement that are allowed only in *At*HPPD,
10 while they are not possible in HPPDs from other species, such as *Rattus norvegicus* HPPD
11 (*Rn*HPPD).²³

24 3.7. Comparison of the complexes between the triketone **14** and HPPD from different organisms

25 A comparison between HPPD structures in complex with **14** (5CTO from *A. thaliana* and 1T47
26 from *S. avermitilis*) resulted in a very similar orientation of the inhibitor within the enzyme
27 binding site (314 residues with a 1.1 Å rmsd, Figure 5). Compound **14** was able to give parallel
28 stacked π - π interactions with the Phe residues and hydrophobic contacts between the CF₃
29 substituent and Leu residues. In the case of 1T47, a nitro- π stacking between the nitro group and
30 Phe336 was also possible, the distance between the centroid of the amino acid phenyl ring and
31 the nitro nitrogen atom being 3.8 Å, in agreement with those reported in the literature (ranging
32 from 3.58 to 5.08 Å).³³ Hydrogen bonds between the inhibitor and the enzyme were not detected.
33
34 Importantly, EPR studies demonstrated that **14** gave a very tight binding to ferrous ion that
35 avoided iron oxidation by dioxygen molecules (O₂), thus permitting crystallization of the HPPD-
36 Fe(II)-inhibitor complexes under aerobic conditions.³⁰ The stability of the triketone/HPPD
37 complexes is very high, with *K_d* values in the picomolar range and a complex dissociation half-
38 time in the hour or day range. For these properties, such compounds have been reported as
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 irreversible inhibitors,³⁰ even though reversion of triketone binding, with consequent reactivation
4 of HPPD, has been demonstrated.
5
6
7
8
9

10 **4. The catalytic reaction**

11
12 The 3D structure of HPPD in its resting state shows a ferrous ion bound to an amino acid triad
13 made of two His and one Glu, while water molecules (or an acetate ion in the case of 1CJX)
14 complete the coordination sphere of the metal into various architectures (i.e., tetrahedral, trigonal
15 bipyramidal, squared pyramidal, octahedral, Table 2). In several cases, the functional iron ion
16 was replaced by Co(II) ions by using cobaltous chloride under crystallization conditions (i.e.,
17 5EC3, 1ISQ).
18
19
20
21
22
23
24
25
26

27 The overall catalytic reaction mechanism leading from the Fe(II)-HPPD/**1** adduct to **2** was
28 studied with theoretical calculations supported by previous experimental data.³⁴⁻³⁷ Three major
29 consecutive steps were identified (Figure 6), consisting of: 1) decarboxylation of **1** to the
30 corresponding acetic analogue (upon binding of the substrate to the ferrous ion and reaction with
31 the dioxygen species); 2) hydroxylation of the phenyl ring; and 3) migration of the acetic side
32 chain to the adjacent position with production of **2**.
33
34
35
36
37
38
39

40 In the first step of HPPD biocatalysis (Figure 6), it was hypothesized that the Fe(II)-HPPD/**1**
41 adduct is attacked by a dioxygen molecule to yield a ferric superoxide anion radical which
42 rearranges into a peracid intermediate *via* oxidative decarboxylation of the α -ketoacid with
43 release of CO₂. Opening of the four-membered ferrous adduct by heterolytic cleavage of the
44 peroxide bond results in a potent oxidant phenylacetic intermediate containing a Fe(IV)-oxo
45 species. The latter is responsible for an electrophilic attack on position 1 of the phenyl ring with
46 consequent de-aromatization and formation of a ring radical σ complex. This is the rate-limiting
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 reaction of the catalytic pathway. Cleavage of the C1-C_{acetic} bond leads to re-aromatization and
4
5 generation of an instable biradical intermediate that initiates the hydroxylation in position 1 and
6
7 the peculiar migration of the acetic side chain to position 2 of the ring. For this purpose, the 4-
8
9 hydroxy-cyclohexandienone undergoes tautomerization (by a direct proton transfer mediated by
10
11 the carboxyl group and without any contribution from the solvent)³⁴ and to re-aromatization. The
12
13 resulting final product is the complex between HPPD, the Fe(II) cofactor, and **2**.
14
15

16
17 Alternative rearrangements of the ring radical σ complex or the Fe(IV)-oxo intermediate leading
18
19 to an arene oxide were hypothesized as well (Figure 7). For engineered HPPD (P214T and F337I
20
21 mutants of *Pseudomonas fluorescens* strain P.J. 874), a rearrangement of arene oxide into an
22
23 oxepine derivative further evolving by tautomerization into the corresponding oxepin-5-one was
24
25 suggested.³⁸ Alternatively, opening of the epoxide ring of the arene oxide or a rearrangement of
26
27 the ring radical σ complex could yield the quinolacetate that reacted with cysteine residues by
28
29 Michael addition, giving hawkinsin in N245S mutant of *S. avermitilis*.³⁹
30
31

32
33 Several steps of the HPPD catalytic cycle are still experimentally inaccessible, and only a few
34
35 reactive intermediates have been identified so far. Hence, alternative mechanistic hypotheses
36
37 involving different intermediate chemical species from those reported in Figure 6 and 7 were
38
39 proposed by means of computational studies.⁴⁰ An in depth analysis of HPPD, both in terms of
40
41 structure, complex formation, and catalytic cycle has been recently published.^{17,18,35,41}
42
43
44
45
46
47

48 49 **5. The fate of HGA in plants and mammals**

50
51 Fate of **2** differs in plants and humans. In plants (Figure 8),⁴² following an anabolic pathway, **2** is
52
53 first decarboxylated, then nonaprenylated at position 3 to give 2-methyl-6-nonaprenyl-1,4-
54
55 benzoquinone (MNPBQ, **5**), and finally methylated at C6 to yield plastoquinol-9 (also referred to
56
57
58
59
60

1
2
3 as plastoquinone in its diketo form). Importantly, the plastoquinol/plastoquinone redox system is
4
5 involved in the photosynthetic electron transport chain that allows for phytoene desaturase-
6
7 mediated oxidation of phytoene to carotenoids.⁴³ On the basis of this pathway, inhibition of
8
9 pigment biosynthesis by repression of the HPPD activity and production of **2** results in
10
11 photodestruction of chlorophyll and whitening of plant tissues (the bleaching effects).
12
13

14
15 Alternatively, **2** can be first decarboxylated, then phytylated at position 3 to give 2-methyl-6-
16
17 phytyl-1,4-benzoquinone (MPBQ, **6**). Ring closure and a subsequent methylation at C5 yields δ -
18
19 and β -tocopherol, respectively. On the other hand, methylation of **6** at C3 produces the
20
21 corresponding dimethyl derivative 2,3-dimethyl-6-phytyl-1,4-benzoquinone (DMPBQ) that
22
23 undergoes ring closure and subsequent methylation at C5 yielding γ - and α -tocopherol,
24
25 respectively.
26
27

28
29 Chemical reactivity of **2** seems to be different as well. It is reported as the main phenolic
30
31 compound with significant antioxidant activity in Sardinian “bitter honey” (a monofloral honey
32
33 from *Arbutus unedo*, Ericaceae).⁴⁴ In fungi and bacteria, **2** undergoes oxidation and
34
35 polymerization into pyomelanin, which serves as protection from sunlight and oxidative attack by
36
37 host cells.⁴⁵⁻⁴⁷ Conversely in humans, where **2** is accumulated upon mutations of HGD, **2** shows
38
39 an outstanding propensity to oxidation into the corresponding quinone (Figure 9) with generation
40
41 of ROS and polymerization into a black substance referred to as ochronotic pigment, not well
42
43 defined in terms of composition and structure. Urine blackening and deposition of black pigments
44
45 in cartilage, epidermis, and sclera are typical of an autosomal recessive human disease known as
46
47 alkaptonuria.¹⁶
48
49
50
51
52

53 54 55 56 **6. Evaluation of HPPD catalytic activity** 57 58 59 60

HPPD catalytic activity can be evaluated through different assays, as follows:

1) Monitoring the formation of a complex between the enol form of **1** with orthoboric acid which absorbs at 308 nm.⁴⁸

2) Monitoring the production of **2**.⁴⁹ For instance, Dayan and co-workers overexpressed recombinant HPPD from *A. thaliana* in *E. coli* and treated the cell-free extract with various concentrations of HPPD putative inhibitors together with the natural HPPD substrate **1**. The reaction was stopped after 15 min and the amount of **2** was quantified by HPLC (detection based on UV absorbance at 288 nm). Changes in oxygen consumption during HPPD-dependent reaction on **1** were monitored as well.

3) Monitoring changes in dissolved oxygen concentration over the time by using Clark electrode or SensorDish technology. For instance, rat liver homogenates could be used as the source of HPPD whose activity could be inferred by monitoring either the uptake of molecular oxygen or the release of ¹⁴CO₂ from a [¹⁴C]-labeled substrate.⁵⁰⁻⁵²

7. Activity of HPPD inhibitors and their selectivity in plants

Although the amino acids that constitute the HPPD binding site are conserved among various species, there are inhibitors that show selectivity toward enzyme from plants or animals. One of the reasons of this selectivity could be ascribed to significantly different K_d values: differences of two or more orders of magnitude correspond to slight differences in energy and are not easily perceivable by structural analysis of the HPPD/inhibitor complexes. Another important parameter to be considered for selectivity is the duration of biological action, expressed in terms of residence time (defined as $1/K_{off}$) of the inhibitor within the HPPD binding site.⁵³ Additional factors could also contribute to inhibitor selectivity. As an example, selectivity of mesotrione (**16**,

1
2
3 an HPPD inhibitor belonging to the triketone class, Figure 10) for maize is mainly attributable to
4
5 the higher potency of this compound toward dicotyledonous plants in comparison to
6
7 monocotyledons (such as the same maize), as well as to the fact that foliar uptake of the herbicide
8
9 is slower in maize than in other plants. However, the rapid metabolism by maize seemed to be the
10
11 most significant parameter for selectivity of **16**.⁵⁴ The distinction between selective and non-
12
13 selective HPPD inhibitors lost its importance when genetically-modified and herbicide-tolerant
14
15 crops able to resist to non-selective compounds (such as glyphosate) were selected. An additional
16
17 example was a transgenic soybean that was designed with an optimized HPPD to become
18
19 resistant to triketones (namely, **16** and tembotrione, **17**, Figure 10), as well as to isoxaflutole (**23**,
20
21 Figure 11). Also in this case, the known selectivity of HPPD inhibitors toward maize crops was
22
23 overridden by a certain number of mutations that rendered the soybean insensitive to such
24
25 compounds.⁵⁵
26
27
28
29
30
31
32
33

34 **8. Timeline of HPPD inhibitors marketed as herbicides**

35
36 The story of small molecules acting as HPPD inhibitors and marketed as bleaching herbicides
37
38 began during the eighties with benzoylpyrazoles such as pyrazolynate (**7**), pyrazoxyfen (**8**), and
39
40 benzofenap (**9**, Figure 10).⁵⁶⁻⁵⁸ In the nineties, the first triketone (**15**) was commercially available,
41
42 followed by the first isoxazole compound (**23**). In the next decade, **16**, benzobicyclon (**21**), **17**,
43
44 and tefuryltrione (**18**) were marketed among the triketones, while topramezone (**12**) and
45
46 pyrasulfotole (**13**) belong to the pyrazole class. Recently, an additional triketone (namely,
47
48 bicyclopyrone **19**) has been registered in the USA as a pesticide for the treatment of corn.⁵⁹
49
50 Moreover, fenquinoatrione (**20**) and the pyrazole prodrug tolpyralate (**10**) are under development
51
52 for weed control in rice and in corn, respectively.⁶⁰
53
54
55
56
57
58
59
60

1
2
3 Studies on HPPD inhibitors will probably increase in the next years because of the onset of
4 resistant weeds. Since 2009 at least two species of *Amarantus* (Amaranthaceae) have been found
5 to be resistant to HPPD inhibitors in the USA.⁶¹ This means that new active ingredients able to
6 selectively inhibit the growth of weeds at low concentrations will be required in the near future.
7

8
9
10 Several of the currently available HPPD inhibitors are prodrugs (in the field of agrochemicals
11 they are referred to as procides, that is pro-herbicides) that need to be transformed into the
12 corresponding active ingredients to chelate iron ions of the HPPD binding site. As an example, 4-
13 benzoyl-5-aryl-pyrazoles undergo degradation (by hydrolysis in water or in plants, as well as by
14 microbial activity) that affects the C5-pyrazole substituent to yield the common 4-benzoyl-5-
15 hydroxy-pyrazole as the active compound (Figure 10).⁶²⁻⁶³ In a similar way, **21** is transformed
16 into the corresponding active triketone derivative **22** by a base-catalyzed nucleophilic addition
17 with consequent release of the thiophenolate anion.⁶⁴⁻⁶⁵ Finally, **23** shows HPPD inhibitory
18 activity upon isoxazole ring opening to the linear diketonitrile **24** (Figure 11).⁶⁶
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **9. Small molecules as inhibitors of HPPD: triketones**

37 *9.1. Serendipitous discovery of triketones as HPPD inhibitors*

38
39 The story of HPPD inhibitors began with the serendipitous observation that the growth of plants
40 and weeds in the field area under the red bottlebrush plant (*Callistemon citrinus*, Myrtaceae) was
41 strongly disfavored in comparison to the adjacent parts of the field.⁶⁷ It was immediately clear
42 that neither the shade created by the bottlebrush plant nor its litterfall were responsible for growth
43 inhibition of other plants. Thus, the presence of allelopathic substances in the soil was
44 hypothesized to account for the suppression of plant growth. To check for this hypothesis,
45 samples of soil under the bottlebrush plant were submitted to solvent extractions and the resulting
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 fractions were assayed for their herbicidal activity. The sole fraction that showed a significant
4 bleaching activity on the emerging plants contained an active ingredient later identified as the
5 isovaleryl syncarpic acid, an already known compound previously named as leptospermone (**26**,
6 Figure 12) for its occurrence in the essential oils of the *Leptospermum flavescens* (Myrtaceae).⁶⁸
7
8 Similar results were obtained starting from fresh leaves of *C. citrinus*. Although **26** was
9 demonstrated to be an allochemical agent,⁶⁹ the possibility to transform it or one of its derivatives
10 into an herbicide was however unrealistic mainly because of its weak activity. As a consequence,
11 studies on these compounds were discontinued.
12
13
14
15
16
17
18
19
20
21

22 9.2. Additional triketones from natural sources: congeners of **26**

23
24 In addition to *Callistemon* spp., other Australasian Myrtaceae were found to produce β -triketones.
25
26 As an example, the steam distilled oil of *Leptospermum scoparium* (Myrtaceae, also referred to
27 as essential oil of manuka), in addition to the already known **26**, also contains a series of its
28 derivatives with different hydrophobic chains attached at the *exo*-carbonyl group.⁷⁰ Among them,
29 grandiflorone (**27**, Figure 12) showed an IC₅₀ value (measured as changes in oxygen consumption
30 to convert **1** to **2**) toward *At*HPPD about three-fold higher than that of **15** (750 vs 250 nM,
31 respectively), while significantly better than that of **26** (750 vs 11800 nM, respectively, 15-fold
32 more active).^{49,71} Interestingly, introduction of a long alkyl chain (a nonyl group as in **28**) led to a
33 19 nM activity. Accordingly to a previous hypothesis suggesting that the nature of the binding to
34 HPPD was dependent from the substituent at position 2 of the cyclohexandione ring,^{50,51} these
35 naturally-occurring compounds and their derivative were time-independent competitive
36 reversible inhibitors due to the fact that they had a 2-alkyl (**26** and the nonyl derivative **28**) or 2-
37 phenetyl moiety (**27**). Differently, synthetic compounds bearing a electron-deficient aromatic ring
38 (i.e., bearing electron-withdrawing substituents at the *ortho*-position and, preferably, also at the
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 *para*-position) usually resulted to have a tight binding toward HPPD to be considered as
4
5 irreversible inhibitors.^{50,51} The high activity of **28** was impossible to account for by a simple
6
7 relationship between IC₅₀ and compound lipophilicity. However, a CoMFA study on these
8
9 triketones showed that the steric properties of the compounds contributed for 66% activity, while
10
11 only 34% was due to the electrostatic components.⁷¹ This model accounted for the high activity
12
13 of the nonyl derivative **28**. In fact, a region of the space identified by the model as profitable for
14
15 activity was occupied by the terminal edge of the linear alkyl chain. Moreover, docking
16
17 simulations showed that the same linear appendage was accommodated within a lipophilic pocket
18
19 of the *At*HPPD binding site. Unfortunately, although their availability in large amounts from
20
21 natural sources, these compounds showed poor pharmacokinetic parameters in comparison to
22
23 those found for commercially available triketones obtained by SAR optimization and synthesis.
24
25 Because of their limitation, naturally-occurring compounds similar to **26** and their derivatives
26
27 were not further profiled.
28
29
30
31
32

33 34 9.3. The benzoyl-cyclohexanedione core discovered as a reaction by-product

35
36 Serendipity was further invoked when, in the attempt to synthesize setoxydim (**29**) derivatives
37
38 as herbicide agents (Figure 13), the benzoyl dimedone derivative **30** was obtained as by-product
39
40 of the synthesis pathway. Subsequent structural optimization by small changes at both the cycles
41
42 led to very active compounds and laid the foundation for SAR (Figure 14), thus suggesting that
43
44 an electron withdrawing group at position 2 of the phenyl ring is fundamental for activity.⁷² In
45
46 particular, such a substituent should carry out two tasks at the same time:⁷³ rendering the phenyl
47
48 ring an electron deficient moiety able to interact by π - π stacking with aromatic amino acids of the
49
50 HPPD binding site, and blocking position 2 thus avoiding an intramolecular cyclization to the
51
52 corresponding dihydroxanthone (Figure 15). In alternative, an undisplaceable non-electron
53
54
55
56
57
58
59
60

1
2
3 withdrawing group (such as a methyl) could occupy position 2, while another electron
4
5 withdrawing moiety should be placed preferably at position 4 of the phenyl ring. Overall, the
6
7 ability of the substituents at both positions 2 and 4 to render the aromatic ring an electron-
8
9 deficient moiety is also related to the acidity of the molecule, the enol tautomer of triketones
10
11 being the vinylogue of the benzoic acid. On such bases, more electron-withdrawing substituents
12
13 at the phenyl ring are responsible for higher acidity of the compound. Finally, introduction of
14
15 alkoxy groups at the *meta*-position resulted in further increased activity toward HPPD. The
16
17 hypothesis that a pocket able to accommodate such substituents could be present in the protein
18
19 was next confirmed by X-ray structures of the HPPD/**14** complexes (5CTO and 1T47) where it is
20
21 clear that the substituent at the *meta*-position could be located within a cavity accessible to the
22
23 solvent.⁵⁶
24
25
26
27
28

29 Combining structural optimization and taking into account herbicidal selectivity (in part
30
31 dependent from different metabolism among plants) and soil persistence, **15** was the first
32
33 triketone derivative to be commercially available as maize selective herbicide. It was followed by
34
35 **16**, whose registered name (Callisto) was reminiscent of *Callistemon*. Compound **16** was found
36
37 to be about 100-fold more active than **26** in pre- and post-emergence treatments, and showed
38
39 broad activity and excellent maize selectivity. Further attempts to modulate soil persistence, crop
40
41 selectivity, and animal toxicology led to the discovery of thousand additional triketones,
42
43 including **14**.
44
45
46
47

48 *9.4. Mechanism of action of triketones*

49

50 *9.4.1. Triketones do not inhibit phytoene desaturase.* The discovery of the mechanism of action
51
52 of triketones was a very challenging and fascinating task. The bleaching properties of these
53
54 compounds suggested their ability to interfere with the production of plant pigments, such as
55
56
57
58
59
60

1
2
3 tocopherols and carotenoids which also serve to protect chlorophyll from sunlight degradation. In
4
5 addition, the significant increase in phytoene concentrations upon herbicidal treatment led to the
6
7 hypothesis that triketones could act at the level of phytoene desaturase (an enzyme involved in
8
9 the synthesis of carotenoids), resulting in phytoene accumulation. However, in vitro activity of
10
11 this enzyme was not affected by none of the triketone herbicides,⁷⁴ thus leading to the conclusion
12
13 that the molecular target of these compounds was different from phytoene desaturase.
14
15

16
17 *9.4.2. Triketones do not inhibit Tyr hydroxylase (TH).* On the other hand, classes of TH inhibitors,
18
19 sharing a common triketone structural motif, were already known as bleaching herbicides. This
20
21 fact prompted the researchers to check whether **14** and congeneric compounds could act as TH
22
23 inhibitors. For this purpose, a colorimetric assay showed the presence of *p*-hydroxyphenyl
24
25 compounds (Tyr belongs to the same chemical class) in the urine of rats upon treatment with **14**,
26
27 while a 20-fold increase in plasma Tyr concentration (from about 0.1 mM to more than 2 mM)
28
29 was found in comparison to controls. Although these results were both in agreement with TH
30
31 inhibition, an in vitro enzymatic assay showed that **14** was not able to inhibit directly TH activity.
32
33 An in depth analysis on chemical composition of urine also showed the presence of unusually
34
35 high amounts of compounds derived from Tyr metabolism, such as **1** and *p*-hydroxyphenyllactic
36
37 acids. This result, combined with the fact that **1** was known to be a substrate for HPPD, led to
38
39 experimental evidence that triketones act as inhibitors of rat liver HPPD.⁵⁰ In particular, studies
40
41 aimed at evaluating changes in oxygen consumption by rat liver HPPD treated with triketones
42
43 showed a time-dependent inhibition of the enzyme *via* a competition with the substrate **1**.
44
45 Compound **14** (50 nM) was able to reduce rat liver HPPD activity by 50% in 30 sec with an IC₅₀
46
47 value of about 40 nM.⁵⁰ HPPD activity was partially restored by increasing substrate levels or, by
48
49 itself, over 7 h (about 13% activity recovery). Experimental evidence definitely showed that
50
51
52
53
54
55
56
57
58
59
60

1
2
3 triketones are characterized by a tight but reversible binding to rat liver HPPD,⁵¹ with an half-life
4
5 of about 63 h for **14**.
6

7
8 *9.4.3. Triketones do inhibit HPPD and cause the bleaching effect.* Identification of HPPD as the
9
10 unique molecular target of triketones allowed to account for bleaching symptomatology in
11
12 plants.⁷³ In fact, inhibition of HPPD-mediated conversion of **1** into **2** abrogates the biosynthesis
13
14 of either tocopherols or plastoquinone (Figure 8). The latter compound is required for the
15
16 biosynthesis of carotenoids from phytoene, mediated by phytoene desaturase. Carotenoids are
17
18 required to quench light-dependent singlet oxygen that is responsible for degradation of the
19
20 photosynthetic assembly and breakdown of leaf pigment (the bleaching effect). In summary,
21
22 treatment of plants with triketone herbicides is responsible for HPPD inhibition and results in the
23
24 so-called triketone effect,⁷⁵ consisting in a significant increase of Tyr levels and a drop of
25
26 plastoquinone concentration, with the consequent appearance of leaf bleaching.
27
28
29
30

31
32 A detailed survey of literature papers and patents dealing with the discovery of triketones and
33
34 their development for agrochemical purposes has been recently reported.⁷⁶
35

36 *9.5. A correlation between inhibitory activity of triketones and their keto-enol isomerization*

37
38 An interesting study on the correlation between HPPD inhibitory activity of triketones and their
39
40 ability to give keto-enol isomerization (Figure 16) provided experimental evidence on their
41
42 mechanism of action at the level of the HPPD binding site. Triketones were already known as
43
44 competitors of the natural HPPD substrate **1**. Several analogues of **14** were designed to check for
45
46 the importance of the keto-enol isomerization, as well as to evaluate whether the triketone system
47
48 was a mandatory structural requirement for pig liver HPPD inhibitory activity.⁷⁷ Several
49
50 triketones (i.e., **31** and **32**, Figure 17), found to have a submicromolar activity (ranging from 160
51
52 to 700 nM), also returned a colored solution when treated with ferric ions, thus suggesting the
53
54
55
56
57
58
59
60

1
2
3 presence of free phenolic hydroxyl groups within their structure, which accounts for a keto-enol
4
5 tautomerization. Moreover, both the triketo and the endo-enol forms of **14** were ruled out as a
6
7 result of NMR studies, thus demonstrating that the exo-enol form was the sole tautomer present
8
9 in aqueous solution at neutral pH.^{30,73} This result was however in contrast with those reported by
10
11 X-ray crystallographic studies,⁷⁷ NMR experiments, and theoretical simulations⁷⁸ that proposed a
12
13 predominance of the endo-enol form of triketones.
14
15

16
17 X-ray crystallography clearly demonstrated that active compounds were characterized by an
18
19 almost planar β -diketo system, which was required for tautomerization to occur. Additional
20
21 experimental details, such as bond length and UV absorption, supported the hypothesis of an
22
23 extensive conjugation within the triketone moiety. In further agreement, replacement of one of
24
25 the cyclohexandione carbonyl groups of **31** (Figure 17) with a MeO substituent led to **33**, whose
26
27 activity decreased by at least two orders of magnitude (from 0.16 to 52 μ M, respectively),
28
29 because of steric clashes that forced the cyclohexane ring out of the plane of the external
30
31 carbonyl (about 60 degree dihedral angle), with a consequent loss of conjugation. These results
32
33 indicate that inhibitory activity is related to the presence of a β -keto-enol system mimicking the
34
35 α -ketoacid of the natural substrate in coordinating the iron ion at the HPPD binding site.
36
37 Coplanarity of the external carbonyl group and the cyclohexanedione ring is also required to
38
39 allow for keto-enol tautomerization. Finally, only one of the two carbonyl groups on the
40
41 cyclohexane ring is necessary (**32** retained a 0.7 μ M activity), while the external carbonyl is a
42
43 mandatory requirement (**34** showed a 126 μ M activity).
44
45
46
47
48
49
50

51 *9.6. In vitro evaluation of triketones in human fibroblasts*

52
53

54 In a recent paper, twelve triketone derivatives and **23** were assayed for their ability to inhibit rat
55
56 liver HPPD activity, for their cytotoxicity toward human primary fibroblasts, and to affect
57
58
59
60

1
2
3 intracellular Tyr levels.⁵² As a result, in addition to **16**, two benzoyl dimedone derivatives (**35** and
4
5 **36**, Figure 18) showed a very interesting biological profile. Inhibition of the enzyme activity was
6
7 measured on the basis of oxygen consumption and led to IC₅₀ values in the two-digit nanomolar
8
9 range (37, 36, and 60 nM, respectively). Cytotoxicity was quantified in a MTT assay and found
10
11 to be higher than 1 mM for the three compounds at 24 and 144 h after administration. Tyr
12
13 accumulation induced by **35** was about 7% lower than that found for **14** at the highest
14
15 concentration tested (0.1 μM). In disagreement with previous reports on different in vitro and in
16
17 vivo models, **16** caused a decrease of Tyr concentration (about 14%) at the highest dose.
18
19 Although this result was ascribed to the activation of alternative pathways able to catabolyze Tyr
20
21 excess (i.e., it is known that inhibition of rat HPPD by **15** is able to increase enzymatic activity of
22
23 TAT),⁷⁹ in-depth studies are required to gain insight on this surprising trend.
24
25
26
27
28

29 *9.7. Additional HPPD inhibitors: small molecule hybrid compounds bearing the triketone core*

30
31 Starting from a benzoylcyclohexane-1,3-dione (Figure 19) as the scaffold already known to bind
32
33 HPPD and to inhibit its enzymatic activity, simple substituents were used to decorate position 2
34
35 of the aromatic ring. Enzymatic activity of purified pig liver HPPD was monitored
36
37 spectrophotometrically. Although electronegative group (Cl, Br, I, nitro, and CF₃) led to
38
39 submicromolar inhibitory activity (from 0.16 to 0.76 μM) up to 70-fold better than the
40
41 corresponding unsubstituted analogue (11 μM), these compounds were not further studied
42
43 because their activity was significantly lower than that of **14** in the same assay (40 nM). On the
44
45 other hand, an interesting attempt of molecular hybridization was experimented. In fact, HPPD is
46
47 also known to catalyze the conversion of α-ketoisocaproate (thus bearing a diketo moiety) to β-
48
49 hydroxyisovalerate in the metabolism of leucine. As a consequence, the aromatic moiety of the
50
51 previous compounds was replaced by an *i*-Pr group (**37**), as found in the isocaproate, or with
52
53
54
55
56
57
58
59
60

1
2
3 linear and branched alkyl moieties. Unfortunately, the cyclopropyl derivative **38** was the sole
4
5 compound that maintained a micromolar activity (6 μM), while the corresponding *i*-Pr analogue
6
7
8 **37** was 15-fold less active (93 μM).^{80,81} This difference in activity was ascribed to the different
9
10 conformational properties of the cyclopropyl moiety in comparison to the structurally similar *i*-Pr
11
12 group, being the first substituent blocked in a conformation characterized by the cyclopropyl
13
14 plane bisected by the plane of the adjacent carbonyl group, with the *i*-Pr being free to rotate.
15
16

17
18 In a parallel way, maintaining a structural feature reminiscent of the β -diketone system, a series
19
20 of cyclohex-2-en-1-one esters was designed (Figure 19).⁸² Also in this case, the cyclopropyl
21
22 derivative **39** was the most active compound (30 nM toward pig liver HPPD), while simple linear
23
24 and branched alkyl groups were detrimental for activity, whose values spanned micromolar
25
26 concentrations. Halogens at position 2 led to more active compounds (**40** and **41** with 15 and 28
27
28 nM activity, respectively), while other substituents at the same position were not tolerated.⁸³
29
30 Attempts to modify the cyclohexenone scaffold led to unprofitable results, with the sole
31
32 exceptions of a contracted five-membered ring as in **42** or a coumarin moiety as in **43**, which
33
34 maintained a 70 and 110 nM activity, respectively.
35
36
37

38
39 Interestingly, the 5-carboxyethyl ester of **38** (**44**), already known as an inhibitor of another non-
40
41 heme Fe(II)- and α -keto acid-dependent dioxygenase (namely, GA₂₀ 3 β -hydroxylase, involved in
42
43 the biosynthesis of gibberellins in plants), was considered as a putative good starting point for
44
45 further optimization of HPPD inhibitors, because of its triketone scaffold.⁸⁴ On this basis,
46
47 molecular hybridization by merging **39** and **44** led to the trisubstituted cyclohexenone **45** with a
48
49 pig liver HPPD inhibitory activity comparable to that of **14** (40 nM). Such a compound and its
50
51 congeners were however abandoned because both the ester moieties showed a significant liability
52
53 in aqueous solution.⁸⁴
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

9.7.1. *Triketone-based hybrid compounds: quinazolindiones.* Additional hybrid compounds were also synthesized starting from the classical triketone scaffold based on a cyclohexane ring and a quinazolindione moiety (Figure 20).⁸⁵ A SAR analysis clearly showed that compounds bearing an unsubstituted cyclohexane ring had better inhibition constants (K_i) of the *AtHPPD* enzymatic activity, in the range of two-digit nanomolar concentrations. Exceptions were represented by *N1*-aryl derivatives that were about one order of magnitude less active. The most active compound (**46**) showed a three-fold higher activity compared to **16** (5 versus 13 nM, respectively). Moreover, while a mono-methyl substitution at the cyclohexane ring maintained a two-digit nanomolar activity, a *gem*-dimethyl pattern generally resulted in a decrease in activity. In order to further improve *AtHPPD* inhibitory activity, a series of *N1*-methyl analogues bearing various substituents at the 5-position of the quinazoline core, at the pendant phenyl ring, as well as at the cyclohexyl ring was synthesized and tested. Many of the new compounds maintained a two-digit nanomolar activity toward *AtHPPD*, although none of them was more active than **46**.⁸⁶

9.7.2. *Triketone-based hybrid compounds: quinolines.* A series of very active compounds was obtained changing the quinazoline core with a quinoline ring bearing the triketone system at position 3 (Figure 20).⁸⁷ In particular, given a methyl group at position 8, the most profitable substituents were a methyl, methoxy, or cyano group at position 2 of the quinoline and a H or Me at position 5 of the cyclohexane. These compounds showed a 7-9 nM activity (expressed as K_i), better than that of **16** (13 nM). Both quinazoline and quinoline compounds were assayed for their activity as herbicides, crop selectivity, and ability to inhibit *AtHPPD* in vitro, but they were not further evaluated toward human HPPD.

9.7.3. *Triketone-based hybrid compounds: lengthening the aryl side chain.* In the attempt to find more profitable interactions between the aryl side chain of the triketone moiety and the aromatic

1
2
3 residues surrounding the *At*HPPD binding site, the classical benzoyl group at the position 2 was
4 extended by insertion of a -CH₂-O- spacer (Figure 20).⁸⁸ Many of the resulting compounds
5
6 showed K_i values in the micro- or submicromolar range, one or two orders of magnitude higher in
7
8 comparison to that found for **17** (13 nM). The best compounds in terms of affinity and plant
9
10 selectivity were found by introduction of a methyl or chloro group at the ortho position and a
11
12 electron-withdrawing substituent at the para position. Their affinity ranged between 31 and 37
13
14 nM. Interestingly, one of these compounds was described as the first HPPD inhibitor with good
15
16 safety toward canola.
17
18
19
20
21

22 23 24 **10. Pyrazole derivatives**

25
26 Another important class of HPPD inhibitors is represented by pyrazole derivatives (Figure 10).
27
28 The pyrazoles showed the common structural motif shared by the triketone HPPD inhibitors, that
29
30 is an α,α -diketo system able to undergo to enolization and to bind an iron ion within the HPPD
31
32 binding site, as well as an electron-deficient benzoyl moiety with a benzene ring bearing an ortho
33
34 substituent. Similar to the case for triketones, binding of the pyrazoles to HPPD and inhibition of
35
36 its enzymatic activity are responsible for bleaching symptoms consequent to pigment
37
38 destruction.⁸⁹ Treatment of photobleached plants with **2** could serve as an antidote to **12**, one of
39
40 the marketed pyrazole derivatives, thus suggesting that HPPD is the target of this compound and
41
42 that the inhibitor is displaceable from the HPPD binding site. As already found for other HPPD
43
44 inhibitors, corn growth is only marginally affected by treatment with **12** and the herbicidal
45
46 activity is favored by acidic pH values. The main reason for corn selectivity was found by means
47
48 of metabolic studies. In fact, after a 48 h treatment, the unchanged compound was found to be
49
50 only 31 and 14 % in foliar and meristematic tissues, while the remaining percentage was
51
52
53
54
55
56
57
58
59
60

1
2
3 represented by the major metabolite *N*1-desmethyl **12** (about 25- and 50-fold less active in vitro
4 toward HPPD and in vivo in plants, respectively) and additional, minor metabolites.
5
6

7
8 Intensive studies on pyrazole derivatives allowed the major relationships between their structure
9 and biological activity to be defined (Figure 21). In particular, small alkyl groups are preferred at
10 the N1 of the pyrazole ring, with a methyl group leading to the most active and plant-selective
11 compounds, such as **12**. Moreover, substituents and substitution pattern on the phenyl ring play a
12 pivotal role in determining activity. A halogen (chlorine is the best) or a small alkyl group (a
13 methyl is preferred, while an ethyl and *t*-butyl group is tolerated) at the *ortho*-position of the
14 phenyl ring is a mandatory condition for high activity. An additional electron-withdrawing
15 substituent at the *para*-position (a -SO₂Me is the best for activity) confers further improvement of
16 activity. Active compounds were also found among 1,2,3,4-tetrasubstituted phenyl derivatives.
17
18 As an example, a *p*-alkoxyphenyl substituent at position 3 of the benzoyl core yielded
19 compounds with activity against weeds and crop selectivity.²⁸
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 *10.1. Pyrazole-based hybrid compounds: pyrazole-quinazolones*

35
36 A scaffold-hopping drug design strategy to find new inhibitors of human HPPD was applied
37 starting from known pyrazole compounds such as **3**, **12**, and **13**. The fact that the quinazolone
38 scaffold was involved in “extensive biological activities” suggested to design hybrid pyrazolo-
39 quinazolones as putative novel HPPD inhibitors (Figure 22).⁹⁰ Despite the seemingly weak
40 rationale of this study, many of the new compounds showed a two-digit nanomolar inhibitory
41 activity toward a human recombinant HPPD, comparable to or better than that found for **14** (K_i =
42 37 nM). Molecular docking simulations were performed with GOLD to check whether the hybrid
43 compounds could be able to interact with the HPPD binding site. An analysis of the resulting
44 theoretical complexes suggested the introduction of a substituted phenyl ring at the N3 of the
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 quinazolone ring with the aim of improving the contacts between the ligand and the enzyme.
4
5 Among compounds of the first series, although populated by *ortho*-halo (F and Cl) derivatives
6
7 with activity of about 80 nM, many showed activity values higher than 100 nM. Such a reduced
8
9 activity (compared to **14**) was attributed to steric clashes between the 3-methyl group of the
10
11 pyrazole ring and the amino acids of the HPPD binding site. On this basis, the additional *des*-
12
13 methyl derivatives were synthesized, which showed a significant enhancement of their activity.
14
15 In particular, electron withdrawing small substituents (such as F, Cl, and Br) at the *ortho* position
16
17 of the phenyl ring were more profitable than a methyl or methoxy group and showed activity in
18
19 the range between 15 and 24 nM. A similar trend with comparable activity values was found for
20
21 the same substituents at the *para* position. The most active compounds showed a *m*-halogen atom
22
23 (F, Cl, and Br with a 20, 10, and 14 nM activity, respectively), although electron-donating groups
24
25 (namely, Me and MeO) maintained a 13 and 34 nM activity, respectively. In general, di-
26
27 substituted derivatives were less active, with the exception of the 2-Br,4-Me analogue (11 nM)
28
29 that was one of the most active compounds.
30
31
32
33
34
35

36 *10.2. Pyrazole-based hybrid compounds: pyrazole-benzimidazolones*

37
38 The same approach was applied to design new pyrazolo-benzimidazolones (Figure 22).⁹¹ Also in
39
40 this case, several of the studied compounds had IC₅₀ values (toward human recombinant HPPD)
41
42 comparable to or better than that of **14** (68 nM). SAR analysis clearly suggested that position 3 of
43
44 the pyrazole ring should be left unsubstituted as already found with previous pyrazole-
45
46 quinazolones,⁹⁰ while alkyl chains of variable length are tolerated at the nitrogen atoms of the
47
48 benzimidazolone moiety. In particular, given a 3-unsubstituted pyrazole scaffold, when a Me, Et,
49
50 or Pr group was placed at one of the benzimidazolone nitrogen atoms, the most active compounds
51
52 were built with a Et, Pr, or *i*Pr substituent at the second nitrogen. Among congeneric compounds,
53
54
55
56
57
58
59
60

1
2
3 inhibitory activity followed the Et \geq Pr>*i*Pr order. Derivatives with bulkier alkyl substituents or
4 aryl moieties underwent a significant drop in activity, up to single-digit micromolar
5 concentrations.
6
7
8
9

10 11 12 **11. Isoxazole derivatives: unexpected HPPD inhibitory activity**

13
14
15 Isoxazole derivatives were first discovered within a research project aimed at finding new
16 inhibitors of the hydroxymethylglutaryl coenzyme A reductase. A pyrimidinedione (**47**, Figure
17 23), whose structure was reminiscent of the already known cyclohexanedione herbicides, showed
18 somewhat activity toward selected weeds.⁶⁶ Expectedly, the next step was the introduction of the
19 benzoyl moiety found in **14**, thus leading to a hybrid triketone system (**48**) with significantly
20 enhanced activity. Opening of the dione ring to a non-cyclic bis-benzoyl compound (**49**) gave the
21 opportunity to find the first benzoylisoxazole (**50**) that was in turn optimized to **23**.
22
23
24
25
26
27
28
29
30

31
32 The significant HPPD inhibitory activity of isoxazole derivatives was unexpected on the basis of
33 the lack of any diketo (enolizable) moiety in their molecular structure. However, as early as
34 1891,⁹² 3-unsubstituted isoxazoles were known to isomerize to α -cyanocarbonyl derivatives
35 when first dissolved in aqueous alkali (such as NaOH) and then neutralized or acidified, as done
36 during the oxygen consumption assay performed to evaluate the HPPD inhibitory activity of **23**
37 and its precursors. The consequent hypothesis was that the 4-ketoisoxazole compounds could
38 give a cyanodiketone derivative responsible for anti-HPPD activity. In agreement, a change of the
39 assay protocol consisting in using a DMSO solution of the putative HPPD inhibitor instead of the
40 aqueous solution resulted in the loss of activity in the case of isoxazole compounds, while all the
41 compounds which had a pre-existing diketone or triketone moiety in their structure (such as **14**,
42 4-keto-5-hydroxy-pyrazoles, and cyanodiketones) maintained the same activity previously found
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in aqueous solution. These results confirmed that activity of isoxazoles toward HPPD was due to
4
5 the formation of their metabolic cyanodiketone derivative (such as **24**, Figure 1), *via* isoxazole
6
7 ring opening that can quickly occur by non-enzymatic hydrolysis both in plants and soils.
8
9

10 An interesting study on the activity of **24** was performed on highly purified HPPD from *Daucus*
11
12 *carota* (carrot, Apiaceae).³¹ Experimental evidence showed a slow and tight binding of **24** to
13
14 HPPD independent of the presence of oxygen, and slow dissociation of the complex (2 h as the
15
16 half-life of the complex), and a $K_d = 6$ nM. These parameters suggested that **24** is a “nearly
17
18 irreversible inhibitor”. Moreover, **24** competes with the substrate **1**, and was able to bind to
19
20 HPPD only in the presence of ferrous ions, thus suggesting that this cofactor was of pivotal
21
22 importance for HPPD/inhibitor complex stabilization, in agreement with that found in X-ray
23
24 complexes where a keto-enol system of the inhibitor was coordinated by an iron ion. The
25
26 stoichiometry of the interaction suggested a half-site occupancy of enzyme, such that only one
27
28 mole of inhibitor was enough to fully inhibit one mole of the dimeric HPPD. The half-site
29
30 occupancy was also confirmed for **24** toward *Pf*HPPD, where two moles of **24** were required to
31
32 inhibit a tetrameric form of HPPD. Half-site occupancy was specific to **24**. In fact, HPPD
33
34 inhibitors belonging to different chemical classes, such as a **15**-like compound, were able to fully
35
36 inhibit HPPD with a 2:1 stoichiometry (two moles of the inhibitor inhibit a mole of the dimeric
37
38 HPPD).
39
40
41
42
43
44

45 The identification and development of heterocyclic inhibitors of HPPD, such as pyrazole and
46
47 isoxazole compounds, has been recently reviewed.⁹³
48
49
50
51
52

53 **12. Common minimum pharmacophoric pattern**

54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Early SAR studies on several classes of HPPD inhibitors, including pyrazoles, isoxazoles and the corresponding cyanodiketone metabolites, triketones, as well as 2-benzoylresorcinols (**51**, Figure 24),⁷⁵ led to the suggestion that the common minimum structural feature shared by these compounds could be represented by an aryldiketone system. In further detail, considering that the β -diketone system undergoes enolic tautomerization in solution, the 2-benzoylethen-1-ol moiety was finally identified as the essential pharmacophore for a significant inhibition of the HPPD enzymatic activity. Further SAR analysis on simple benzoylethenol derivatives showed that the acidity is an important parameter to be taken into account for an efficient inhibition of HPPD, being pK_a values lower than 6 required for an in vivo potent inhibition at least in plants.

13. Benzoyl-benzothiazines

In the search for HPPD inhibitors, a series of benzothiazine dioxide compounds bearing the usual substituted benzoyl moiety at position 3 and the general pharmacophore previously described, was designed (Figure 25).⁹⁴ Among about forty new compounds, the most active entry was **52**, with an *o*-Cl,*p*-SO₂Me substitution pattern on the pendant phenyl ring, reminiscent of **15** and other similar triketones. Unexpectedly, compounds with different substituents at both positions ortho and para (such as the *o*-NO₂,*p*-SO₂Me substitution pattern found in **16** and known to be very profitable for HPPD inhibition) were not tested. HPPD inhibitory activity of **52** (IC₅₀ = 480 nM toward recombinant *At*HPPD) was comparable to that of **15** (530 nM) and slightly lower than that of **16** (250 nM). The herbicidal activity profile of **52** was characterized by a complete growth inhibition for most of the weed plants assayed both in pre- and post-emergence experiments. Unfortunately, none of these new compounds were assayed toward human or mammalian HPPD.

14. Additional HPPD inhibitors from natural sources

The ability of **26** to inhibit HPPD enzymatic activity prompted the researchers to search for alternative naturally-occurring compounds with the same mechanism of action. The first report of a natural compound with bleaching properties described usnic acid **53** (Figure 26), a secondary metabolite of the yellow-green lichen *Alectoria sarmentosa*.⁹⁵ The (-)-enantiomer of **53** induced a dose-dependent inhibition of carotenoid biosynthesis *via* inhibition of *At*HPPD. This compound was described as an irreversible inhibitor of HPPD, similarly to synthetic triketones, such as **15**. In particular, IC₅₀ of **53** was found to be 70 nM, better than that of **15** itself. Activity of **53** toward HPPD was ascribed to its triketone system, known to bind the iron ion and the HPPD binding site.⁹⁶ An attempt to find additional HPPD inhibitors from natural sources led to the biological evaluation of more than 30 small molecules belonging to different chemical classes. However, none of the test compounds showed a better activity in comparison to (-)-**53**.⁹⁷

Another study evaluated the HPPD inhibitory activity of ethanol extracts of 91 plants from central Argentina.⁹⁸ Pinocembrin (**54**, Figure 26), a flavanone derivative, was found to be a reversible and non-competitive inhibitor of pig liver HPPD with an IC₅₀ value of 73 μM. Molecular docking calculations suggested for this compound a binding site within HPPD not overlapping that of other known inhibitors, such as the triketone derivatives. This alternative binding mode, supportive of the non-competitive mechanism of action, was consequent to the presence of the keto-enol moiety within the rigid fused chromenone ring, differently from that found in other HPPD inhibitors that showed a certain structural flexibility.

15. Design of HPP analogues as HPPD inhibitors

1
2
3 In the past, it was hypothesized that the α -carbonyl moiety of **1** could undergo a nucleophilic
4 attack leading to a tetrahedral intermediate. On this basis, derivatives of **1** were designed and
5 synthesized with the α -keto group transformed into the corresponding hydrated form (Figure 27).
6
7
8
9
10 These compounds lacked the possibility to serve as an HPPD substrate and then could inhibit its
11 enzymatic activity by competition with the natural substrate. To prompt the α -keto group to
12 hydration, a fluorine atom was introduced on the methylene bridge of the β -position. The simple
13 3-F-3-phenylpyruvic acid **55** was found to exist only in the hydrated form (>99%) in water or
14 deuterated water. This compound, competitive inhibitor of pig liver HPPD with a weak inhibition
15 constant (about 10 μ M), was not further profiled.⁹⁹
16
17
18
19
20
21
22
23
24
25
26
27

28 **16. Cation chelators as HPPD inhibitors**

29
30 Hydroxamic acids **56-58** were the first compounds of this structural class to be found as HPPD
31 inhibitors (Figure 27). They showed a weak inhibitory activity (in the two-digit micromolar
32 range) toward *At*HPPD in the enol-borate assay.¹⁰⁰ Their mechanism of action was not
33 investigated, even if activity was probably due to their known ability to chelate both bivalent
34 (such as ferrous ions) and trivalent cations. Since a clear correlation between phytotoxicity and
35 HPPD inhibition was not found, it was hypothesized that HPPD was only partially involved and
36 that other targets (such as metalloenzymes) were affected.
37
38
39
40
41
42
43
44
45
46
47
48

49 **17. Computational protocols to find new HPPD inhibitors**

50
51 Following a classical computer-based ligand design, HPPD inhibitors were also used to build and
52 validate both ligand- and target-based virtual screening protocols. The last were in turn applied to
53 both the pharmaceutical and the agrochemical field to allow the identification of compounds with
54
55
56
57
58
59
60

1
2
3 an improved HPPD inhibitory activity.¹⁰¹ In an effort to find new compounds active toward
4 plants, given that the 3D coordinates of the full length HPPD from plants were not available, a
5
6 homology model of the *At*HPPD was built starting from the corresponding structure of *S.*
7
8 *avermitilis*. The modeled structure was then used to perform docking calculations and the
9
10 resulting structural features were then codified into a 3D pharmacophoric model, manually
11
12 adjusted to account for the interactions between the ligand/inhibitor and iron ions. The
13
14 pharmacophore was submitted to a poor validation step, by correlating the experimental IC₅₀ of
15
16 several HPPD inhibitors with their calculated fit values (expressed as the ability of each
17
18 compound to map the pharmacophoric portions of the model).¹⁰² Unusually, neither the
19
20 homology model of *At*HPPD nor the pharmacophore were further used to perform virtual
21
22 screenings and find new small molecules able to affect HPPD activity.
23
24
25
26
27
28

29 Following a different approach, a quantitative theoretical model that correlated the inhibitory
30
31 activity of several phenylquinazolone-pyrazolones already known⁹⁰ with their molecular
32
33 descriptors, such as HOMO and LUMO orbitals, was generated by linear multiple regression
34
35 analysis.¹⁰³ Unexpectedly, the methylated pyrazolone analogues that were reported in the same
36
37 paper and that could allow to enlarge the range of K_i values, were not taken into account to
38
39 generate the model. The resulting best equation suggested the optimal groups to be used as
40
41 substituents at various positions of the phenylquinazolone-pyrazolone scaffold. Also in this case,
42
43 suggestions coming from the quantitative models were not further applied for the identification of
44
45 new HPPD inhibitors, thus not allowing for a full validation of the same models.
46
47
48
49

50 A docking-based computational approach aimed at further optimizing HPPD inhibitors suggested
51
52 that different interactions with the HPPD binding site (not clearly detectable at a visual inspection
53
54 of the corresponding X-ray crystal structure 1SQI and 1TFZ, respectively) and the consequently
55
56
57
58
59
60

1
2
3 different docking energies could be responsible for the high selectivity of **4** for plant enzyme and
4
5 for the non-selective activity of **3** toward both rat and plant HPPD.¹⁰⁴ Based on these
6
7 calculations, two original compounds were proposed. In detail, **4** was transformed into the
8
9 corresponding *N*-1,2,4-dihydroxy-benzoyl analogue, predicted to be more selective toward plant
10
11 HPPD in comparison to its parent compound. On the other hand, an analogue of **3** with a 2,4-
12
13 dichlorophenyl substituent instead of the -SO₂Me group was hypothesized to have a better
14
15 affinity for both plant and rat enzymes. Again, this hypothesis was not fully validated as the new
16
17 compounds were neither synthesized nor tested.
18
19
20
21
22
23

24 **18. HPPD inhibitors in therapeutic interventions: the case of compound 14**

25
26
27 Dysregulation of enzymes involved in the Phe-Tyr catabolic pathway is linked to various human
28
29 diseases. As an example, deficiency of TAT enzyme caused by mutations in *TAT* gene is found in
30
31 type II tyrosinemia (Richner-Hanhart syndrome), an autosomal recessive inherited disease.¹⁰⁵ The
32
33 disease is characterized by hypertyrosinemia with oculocutaneous manifestations and, in some
34
35 cases, mental retardation. Management of the disease includes dietary restriction of Phe and Tyr.
36
37 Such a controlled diet allows lowering of plasma Tyr levels and rapid resolution of the
38
39 oculocutaneous manifestations, though the effects on CNS are less clear.
40
41
42

43
44 Moreover, deficiency of HPPD caused by mutations in *HPD* gene is responsible for type III
45
46 tyrosinemia, where the accumulation of **1** might eventually lead to elevated blood Tyr levels due
47
48 to reversibility of the TAT-catalyzed reaction. The disease is characterized by mild
49
50 hypertyrosinemia and variable clinical pictures.
51
52

53
54 Increased blood Tyr amounts and consequent ocular manifestations are found also in T1T and in
55
56 alkaptonuria patients treated with **14** (see below). Both T1T and alkaptonuria are metabolic
57
58
59
60

1
2
3 diseases arising from defects downstream of production of **2** in the Tyr degradation pathway. In
4 particular, mutations affecting the activity of FAH cause T1T, a fatal disease with autosomal
5 recessive inheritance.¹⁰⁶ The inability of FAH to finalize the Tyr metabolic pathway leads to the
6 non-enzymatic reduction of both fumarylacetoacetate and its precursor maleylacetoacetate into
7 succinylacetoacetate, which is in turn decarboxylated to give succinylacetone (Figure 28). The
8 last two compounds accumulate in high amounts in the liver and kidneys, affecting cellular
9 morphology and organ architecture because of altered redox equilibria. Hepatotoxicity, hepatic
10 lesions, failure and cirrhosis, as well as primary liver cancer can occur. It was also hypothesized
11 that the mutagenic effects of fumarylacetoacetate may contribute to the initiation steps that lead
12 to cancer.¹⁰⁷

13
14 Alkaptonuria is consequent to gene mutations that cause the inability of HGD to catabolize **2**,
15 which is then accumulated. Evidence suggests tha **2** can undergo oxidation into the corresponding
16 benzoquinone derivative (benzoquinone acetate, BQA) whose polymerization yields a black
17 pigment found in connective tissues and urine of affected individuals (Figure 9). Deposition of
18 such a black pigment (a phenomenon known as ochronosis) causes dramatic degeneration of
19 connective tissues in affected organs, mainly joints¹⁰⁸⁻¹¹¹ and cardiac valves,¹¹²⁻¹¹³ although any
20 tissue expressing HGD may be involved.¹¹⁴⁻¹¹⁵

21
22 Blocking the production of succinylacetoacetate/succinylacetone and **2** could represent useful
23 therapeutic interventions to treat T1T and alkaptonuria, respectively. As triketone compounds
24 such as **14** were known inhibitors of HPPD in plants, hypotheses were made on their possible use
25 in these human diseases. In T1T, treatment with **14** led to a significant relief of anemia induced
26 by succinylacetone-dependent inhibition of heme synthesis. The application of **14** as a therapeutic
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 agent for T1T also stimulated work on fumarylacetoacetate and its involvement in mutagenic
4 changes hypothetically responsible for liver tumors in infancy and childhood.
5
6

7
8 Moreover, **14** recently entered clinical trials to evaluate its efficacy and safety in alkaptonuria as
9 well.¹¹⁶ In these cases, as expected, one major side effects found for the use of **14** was a
10 combined effect of accumulation of **1** and its re-conversion in Tyr, which was responsible for
11 corneal opacity and ocular lesions very similar to those found in type II tyrosinemia.
12
13
14
15

16
17 A role for **14** was hypothesized also for hawkinsinuria, a disease characterized by the presence of
18 the unusual cyclic amino acid hawkinsin in urine. Erroneously, it was first hypothesized that
19 hawkinsinuria could be caused by A33T substitution in HPPD, which was later demonstrated to
20 be a polymorphic form of HPPD without pathological consequences. Conversely, the mutation
21 responsible for hawkinsinuria in humans involves a N241S substitution, leading to enzyme
22 activity loss and production of hawkinsin through a quinolacetic acid intermediate (Figure 7).
23
24 From a mechanistic point of view, the quinolacetic acid undergoes first a Michael addition
25 involving cysteine amino acids, then keto-enol tautomerization and reduction of ene system ensue
26 to yield hawkinsin. Fortunately, hawkinsinuria is a temporary disease whose symptoms,
27 described as failure or inability to thrive, disappear after the first 1-2 years of life. Considering
28 that the N241S variant of HPPD is susceptible to the inhibitory activity of **14** probably because
29 “the mutation does not change the binding mechanism significantly”,³⁹ such a compound could
30 be used in the very first years of life of infants suffering from hawkinsinuria.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 **19. Pharmacokinetics and Toxicity of HPPD inhibitors in mammals**

52
53 Early studies on the toxicity of triketones were focused on experimental animals, such as rats and
54 mice. In particular, the mechanism of action established for **16** on mammals was based on a
55
56
57
58
59
60

1
2
3 competitive and reversible inhibition of HPPD, with consequent accumulation of its substrate **1**.
4
5 Since the metabolic step catalyzed by TAT is reversible, significant accumulation of Tyr was
6
7 evident as well. TAT enzyme activity is also responsible for species- and genre-dependent
8
9 differences in Tyr accumulation. For instance, male rats treated with HPPD inhibitors can
10
11 accumulate Tyr up to about 3 mM, while two-fold reduced levels can be found in female rats.
12
13 Differently, the highest observed Tyr level in mice was around 0.8 mM. The impressive increase
14
15 of Tyr levels in rats is responsible for a wide panel of adverse effects not found in mice.¹¹⁷ The
16
17 different toxicity in rats and mice, combined with the reduced activity of TAT in rats, suggests
18
19 that adverse effects observed after triketone administration are not related to intrinsic toxicity of
20
21 these compounds, but they are rather consequence of excess Tyr in blood. Further support to this
22
23 hypothesis is provided by the fact that blood Tyr below 0.5 mM is not associated to adverse
24
25 effects. Moreover, when administered at comparable doses in T1T patients, **16** is associated to
26
27 lower Tyr levels respecting to **14**: this is related to a shorter half-life of **16** (\approx 1 hour) compared to
28
29 **14** (\approx 53 hours). Thus, both drug half-life and TAT activity can be considered pivotal elements
30
31 contributing to tyrosinaemia and related side-effects in humans.¹¹⁷
32
33 Hypertyrosinemia induced by **14** is not straightforwardly related to corneal injuries, as
34
35 differences in TAT enzymatic activity play a significant role in modulating **14**-induced ocular
36
37 toxicity. Administration of **14** to mice caused quick suppression of HPPD activity and marked
38
39 increase of Tyr levels in plasma and aqueous humor. However, any ocular toxicity and corneal
40
41 injury was found, differently to what found in rats treated with **14** and in rats fed with Tyr-
42
43 enriched diet.¹¹⁸ Furthermore, hypertyrosinemia induced corneal lesions in dogs but not in
44
45 rabbits.¹¹⁹
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 When **67** was tested in rats to assess its effects on hepatic enzymes involved in Tyr pathway, a
4 quasi-quantitative inhibition of HPPD was found (from 91 to 96% in comparison to control,
5 depending on the dose of **15**) together with a significant decrease (29-46%) in HGD activity and
6
7
8 a significant increase (43-175%) in TAT activity. Such an effect of **15** in TAT activity differed
9
10 from what observed with **14**, which indirectly inhibited TAT through HPPD repression and
11 accumulation of **1**. The same corneal lesions associated to **14** and Tyr-enriched diet were
12 described also with **15**. Partial opacity was observed at week 2 after a 50 and 100 mg/kg/day
13 dosage.⁷⁹ Complete opacity was reached at the end of the treatment (90 days), that regressed one
14 week after discontinuation of administration. A chronic keratitis was also observed, with the
15 epithelium and the stroma that underwent significant structural modifications. Rats treated with
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Different results were reported in humans, where Tyr levels did not increase significantly after administration of **15**, even in cases of poisoning after voluntary ingestion of a commercial herbicide containing **15**.¹²⁰⁻¹²¹ Only transient symptoms were described (such as high plasma concentrations of **15**, mild hypertyrosinemia, and renal failure) that did not evolve in permanent damages. Tyrosinemia was however below the threshold recommended by FDA for treatment with **14**.

Administration of **14** and **16** to healthy male volunteers showed that the two compounds had very different pharmacokinetic and pharmacodynamics profiles, although sharing common portions in their chemical structures. Both were rapidly absorbed and acted as HPPD inhibitors, although

1
2
3 with different magnitude and duration.¹²² In particular, **16** (at the dose of 4 mg/kg body weight)
4 showed a plasma half-life of about 1 h and was rapidly eliminated unchanged in urine. It induced
5 a minimal increase of plasma Tyr from 0.036-0.105 mM (with a controlled diet) to about 0.3 mM
6 within 2 days. Differently, **14** induced a rapid inhibition of the HPPD activity (with a rate
7 constant of $9.9 \cdot 10^{-5} \text{ s}^{-1} \cdot \text{nM}^{-1}$ in rats) followed by a slow complex dissociation (in vitro half-life of
8 63 and 53 h in rats and humans, respectively) with consequent recovery of enzyme activity. This
9 means that **14** is not an irreversible HPPD inhibitor but is characterized by a long residence time
10 in comparison to other triketones; it only competes with the natural substrate for the same
11 binding site. At the dose of 1 mg/kg body weight, **14** showed a persistent activity toward HPPD
12 in human mainly due to its long half-life. A significant increase of plasma Tyr levels was found,
13 from 0.076-0.136 mM (uncontrolled diet) to about 1.1 mM within 120 hours. Background levels
14 of plasma Tyr were restored 2 months after dosing.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 The different pharmacological profiles of **16** and **14** in terms of magnitude, duration of activity
33 toward HPPD and influence on plasma Tyr levels allowed **14** to be used as a drug and **16** as an
34 herbicide. In fact, **14** is currently adopted to treat TIT and is now in advanced clinical trials for
35 alkaptonuria,¹²³⁻¹²⁴ two diseases that require a persistent suppression of HPPD activity for their
36 treatment. On the other hand, **16**, considered as a safe herbicide also in case of systemic exposure
37 during industrial preparation or application in agriculture because of its transient activity toward
38 human and mammalian HPPD, is used to control weeds in maize crop.

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Compound **17**, another member of the triketone class, has been classified as a low risk compound
for most of the terrestrial and aquatic animals and for terrestrial non-target plants, while the most
sensitive species are aquatic plants.¹²⁵ Compound **17** is rapidly absorbed and completely excreted
after 96 h, without significant accumulation, although associated, as expected, to corneal lesions,

1
2
3 as well as liver and kidney toxicity in rats. Risks for consumers or after occupational exposure are
4 significantly below the acceptable cutoff.¹²⁵ Although literature reports did not describe **17** as a
5 genotoxic compound, a recent study on human hepatocellular carcinoma cell line HepG2
6 suggested caution to be taken when using it. In fact, cytogenetic effects were highlighted in
7 HepG2 cells, even if a low cytotoxicity and negligible DNA damage were measured at residential
8 and operator exposure levels (2 and 1.2 mg/mL, respectively).¹²⁶

9
10 Metabolic studies on triketones showed that the main route of metabolism was an hydroxylation
11 at position 4 of the cyclohexyl ring or, alternatively, the same reaction at position 6 (chemically
12 equivalent) in the presence of substituents at position 4. As an example, 4-hydroxyl derivative of
13 **15** was found as the major metabolite of the parent compound in rat urine. In a similar way, a
14 stepwise hydroxylation at the cyclohexyl ring also occurred for **17**. Accordingly, mono and
15 dihydroxylated metabolites of **17** were found both in plants, animals, and soil. These findings
16 allowed to account for different herbicidal activity of compounds sharing the same HPPD
17 binding affinity. In particular, better herbicides were the compounds with the metabolic labile
18 positions occupied by substituents. Despite their higher metabolic stability and herbicidal potency,
19 these molecules were not prioritized because of their lack of selectivity toward maize and
20 increased soil persistence, which can negatively affect crop rotation, particularly soybean crops.⁵⁴

21
22 However, further studies on the same class of compounds led to the identification of **19** and **21**
23 that bear an ethyl bridge linking positions 4 and 6 of the cyclohexyl ring, thus preventing
24 metabolic degradation. They are currently under study for their weed inhibitory activity in rice
25 and corn crops.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Pyrazole derivatives undergo dealkylation at the *N1* pyrazole ring. In fact, the major metabolite
4 of **12** is an *N1*-demethylated derivative that shows a significantly lower activity toward *At*HPPD
5 in comparison to the parent compound (600 vs 23 nM).⁸⁹
6
7

8
9
10 On the other hand, as a general trend for environmental fate, soil metabolites of triketones and
11 isoxazoles are represented by the corresponding substituted benzoic acid. As an example, **15** is
12 found in soil as the 2-chloro-4-methylsulfonyl-benzoic acid metabolite, which is classified as a
13 low risk compound for environmental toxicity. In a similar way, the 2-nitro-4-methylsulfonyl-
14 benzoic acid is found as a metabolite of **16**, in addition to the corresponding amino derivative
15 generated by reduction of the nitro group. Recently, bacterial strains were isolated from soil and
16 cloud water that were able to completely and rapidly degrade **15** and **16**,¹²⁷⁻¹²⁸ chemical entities
17 classified as toxicologically dangerous for the environment.
18
19

20 A recent survey on hygienic classification, sensitivity of experimental animals and toxicity on
21 them, has been reported for the most important triketones, isoxazoles, and pyrazoles used as
22 active ingredients of currently available herbicides.¹²⁹ More complete information on such
23 compounds, including environmental fate (i.e., soil absorption, mobility, and degradation, as well
24 as soil, animal, and plant metabolites), ecotoxicology (LC₅₀ and LD₅₀ in animals, and amount of
25 compounds found in plants), and human health issues could be find at the Pesticide Properties
26 Database (PPDB).¹³⁰
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **20. Triketones inhibitors of HPPD also showed additional biological activities**

49 Both naturally occurring triketones and their synthetic derivatives also showed a wide spectrum
50 of activities toward microorganisms. Compound **14** and other HPPD inhibitors have been
51 patented as tools for the treatment of microbial infections, on the basis of their ability to reduce
52
53
54
55
56
57
58
59
60

1
2
3 the production of pigments in microorganisms. Reduced amounts of pigments are known to
4 increase the susceptibility of microorganisms to drugs. In fact, microorganisms become less
5 resistant to macrophage attack and phagolysosomal fusion when they have a dysregulated
6 production of pigments.¹³¹ In other examples, essential oils from *L. scoparium* (in particular, the
7 so called manuka oil of the Australian tradition)⁷⁰ and from *Melaleuca alternifolia* (Myrtaceae,
8 the so called tea tree oil)¹³² showed antimicrobial activity mainly due to their triketone complex
9 that contained a significant amount of **26** and its analogues. However, only gram-positive bacteria
10 are susceptible to natural triketones^{70,132} and their synthetic derivatives.¹³³ Manuka oil was also
11 found to inhibit the growth of *Herpes simplex* virus type 1 and 2, being **26** and flavesone (two
12 components of the triketone complex) the active compounds.¹³⁴

13
14
15
16
17
18
19
20
21
22
23
24
25
26
27 Recently, a pivotal study on the application of HPPD inhibitors as anti-plasmodial agents has
28 been reported.¹³⁵ A structurally heterogeneous class of β -triketones bearing a syncarpic acid
29 moiety (referred to as watsonianones) were isolated from *Corymbia watsoniana* (Mirtaceae) and
30 assayed as inhibitors of *Plasmodium falciparum*. The most active compound (namely,
31 watsonianone B, **59**, Figure 29) showed a sub-micromolar activity toward both chloroquine-
32 sensitive and -resistant strains of the parasites ($IC_{50} = 0.4$ and $0.3 \mu M$, respectively) and
33 represented an innovative chemotype for inhibition of *P. falciparum*.

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A subsequent study on human parasites led to the discovery that blood-feeding arthropods are
selectively killed by HPPD inhibitors.¹³⁶ Enzymes involved in Tyr degradation (TAT and HPPD)
are overexpressed after a blood meal and their inhibition caused insect death. As an example, **16**
is able to selectively kill blood-feeding arthropods by Tyr accumulation. More interestingly, since
oogenesis was incomplete before death, HPPD inhibitors can also block insect reproduction.
Insects are also killed when they feed on mice treated with **14** (1 mg/kg body weight). Non-

1
2
3 hematophagous insects are not affected by HPPD inhibitors. These results are very important
4
5 because they lay the foundations for new selective insecticides, in principle more active toward
6
7 arthropods that are increasingly resistant to the currently available neurotoxic agents.
8
9

10 HPPD inhibitors have been also patented for their possible application in the treatment of
11
12 depression,¹³⁷ restless leg syndrome and related sleep disorders,¹³⁸ as well as in people suffering
13
14 from Parkinson's diseases (PD).¹³⁹ In these cases, inhibition of HPPD could guarantee elevated
15
16 levels of plasma Tyr that are expected to increase brain dopamine, being Tyr the precursor of
17
18 dopamine itself. Studies on PD were discontinued after a phase 2 clinical trial that "did not show
19
20 a significant improvement in measures of PD motor function when compared to placebo".¹⁴⁰ For
21
22 the remaining studies, no results have been disclosed yet.
23
24
25
26

27 Compound **14** is also currently under phase 1/2 clinical trials for oculocutaneous albinism, type
28
29 1B,¹⁴¹ being able to ameliorate skin and eye pigmentation in a mouse model of the disease.¹⁴²⁻¹⁴³
30
31 In fact, by increasing plasma Tyr levels to millimolar concentrations (about 0.7-0.8 mM) after
32
33 administration of **14** in clinical isolates (from patients with oculocutaneous albinism, type 1B)
34
35 and albino mouse models (4 mg/kg every other day) with a residual tyrosinase activity, tyrosinase
36
37 is stabilized and its activity enhanced. As a consequence, an increase of melanin levels in
38
39 intracellular melanosomes is observed, together with increased pigmentation of both iris and new
40
41 hair in mice. The enhanced pigmentation has been hypothesized to ameliorate the visual function
42
43 in people suffering from albinism type 1B, although a robust correlation between pigment
44
45 deposition and visual function was not demonstrated even in mice.¹⁴² Importantly, on the basis of
46
47 the fact that Tyr could serve as a substrate chaperone for correcting the misfolded tyrosinase in
48
49 cases of oculocutaneous albinism type 2, studies for repositioning of **14** as a drug could be further
50
51 extended to this human disease.¹⁴⁴
52
53
54
55
56
57
58
59
60

21. Conclusion and future directions

This review describes interesting interconnections between agrochemicals and drug-like compounds, the most striking example being studies on plant HPPD inhibitors used in the agrochemical context as bleaching herbicides that led to the repositioning of **14** as a drug for human diseases. In particular, **14** is currently used to interfere with Tyr metabolic pathway to treat T1T, an inherited and fatal disease. Moreover, a possible application of **14** as a drug for the treatment of alkaptonuria is under evaluation in clinical trials. Finally, treatment with **14** could be also beneficial for hawkinsinuria, a transient disease caused by HPPD mutants that are however sensitive to **14**. These considerations highlight the importance of drug repositioning approach in finding new uses for well-known drugs. For **14**, a reasoned (not serendipitous) repositioning was made possible by an in depth analysis of the mechanism of action of triketone herbicides, as well as of their side effects in experimental animals during toxicity assays. Moreover, repositioning of **14** is unique for the fact that, by interfering with the Tyr metabolic pathway, it is possible to treat T1T, alkaptonuria, and (possibly) hawkinsinuria.

Another interesting example falling within the same experimental context and rational design is the serendipitous discovery of the allelopathic properties of triketones from *Callistemon* sp. plants. This was the starting point for design, synthesis, and biological evaluation of a significant number of new chemical entities belonging to different structural classes. Additional efforts for the identification of novel small molecules able to interfere with HPPD enzymatic activity, still ongoing, are summarized in this review.

However, design of an effective and safe HPPD inhibitor to be used as a drug is a challenging task to be issued. Many of the currently available HPPD inhibitors, such as the drug **14**, are

1
2
3 characterized by a rapid inactivation of the enzyme and a long residence time. This means that
4 the HPPD-inhibitor complex is formed very quickly, but it dissociates very slowly (quasi-
5 irreversible inhibition). As a result of the rapid and persistent HPPD inactivation, an unbalanced
6 ratio between suppressed production of **2** and high Tyr accumulation led to important side effects.
7
8 In this context, a fine modulation of HPPD activity is required by means of compounds with
9 reduced residence time. By this way, a partial reactivation of HPPD will guarantee a limited
10 production of **2** and avoid too high levels of tyrosinemia. In particular, a rapid complex
11 dissociation will result in the desired pharmacology, while prolonged residence time will cause
12 unwanted effects.
13
14

15
16 On the other hand, HPPD inhibitors with different pharmacokinetics and pharmacodynamics
17 properties could be selected as safe herbicides. As an example, **16** is characterized by a specific
18 plant selectivity profile that renders this compound an effective herbicide for maize protection. At
19 the same time, on the basis of its short plasma and HPPD-complex half-life in mammals, **16** is
20 considered as a safe herbicide. This means that herbicide selection requires a careful evaluation
21 of toxicity toward the environment and end-user, in addition to have a wide activity for weed
22 control, low application rates, and crop selectivity.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Author information

Corresponding Author

*Phone: +39 0577 234330. E-mail: fabrizio.manetti@unisi.it

Notes

The authors declare no competing financial interest.

Biographies

Annalisa Santucci is a Full Professor of Biochemistry at the Department of Biotechnology, Chemistry and Pharmacy, of Siena University. Author of 200 papers on international peer-reviewed journals, and inventor of 7 patents. Recently, AS developed unique expertise in alkaptonuria physiopathological molecular mechanisms; her group developed a series of in vitro and ex vivo alkaptonuria human models; she discovered secondary amyloidosis and links between inflammation and oxidative stress in alkaptonuria. Member of the Advisory Board of FindAKUre international network. Founder, Vice-President and President of the Scientific Committee of aimAKU (Associazione Italiana Malati di Alcaptonuria). Organizer of six editions of AKU International Workshop (2009-2013) and 1st Italian Meeting on AKU (2015). Several funds obtained for AKU research, including: FP7-HEALTH-2012-INNOVATION-1 - Clinical Development of Nitisinone for Alkaptonuria.

Giulia Bernardini is a Research Assistant in Biochemistry at the Department of Biotechnology, Chemistry and Pharmacy, of Siena University. GB's scientific background is primarily in

1
2
3 biochemistry, with a focus on post-genomics and differential protein expression analysis. Her
4
5 research interests embrace a wide array of scientific topics ranging from proteomics and
6
7 immunoproteomics of pathogen microorganisms, to proteomics and immunoproteomics of
8
9 human samples with regard to different pathologies in particular bone metabolic and
10
11 osteoarticular diseases. Her research is mainly focused in elucidating the molecular basis of
12
13 diseases such as osteosarcoma and alkaptonuria, and developing novel therapeutic approaches.
14
15 Author of 60 papers on international peer-reviewed scientific journals, and inventor of 2 patents.
16
17
18
19

20
21
22 **Daniela Braconi** is a Research Assistant in Biochemistry at the Department of Biotechnology,
23
24 Chemistry and Pharmacy (Siena University). Her scientific background is primarily in
25
26 biochemistry, with several proteomic and immunoproteomic studies related to microorganisms
27
28 and human diseases, paying particular attention to oxidative post-translational modifications of
29
30 proteins. In the last years, she focused on the elucidation of molecular mechanisms underlying
31
32 the rare disease alkaptonuria. She is author of 48 papers in international peer-reviewed scientific
33
34 journals.
35
36
37
38
39

40
41 **Elena Petricci** is Researcher of Organic Chemistry at the Department of Biotechnology,
42
43 Chemistry, and Pharmacy of the University of Siena, Italy. Her research activity is focused on the
44
45 application of innovative techniques and methodologies for the synthesis of small molecules
46
47 within drug design and development research projects.
48
49
50

51
52
53 **Fabrizio Manetti**, Ph.D., is Associate Professor of Medicinal Chemistry at the Department of
54
55 Biotechnology, Chemistry, and Pharmacy of the University of Siena, Italy. He is co-founder of
56
57
58
59
60

1
2
3 Lead Discovery Siena, a spinoff operating in the field of drug design and lead optimization. His
4
5 research activity is focused on the application of ligand- and structure-based drug design
6
7 approaches to find biologically active small molecules.
8
9

10 11 12 **Abbreviations used**

13
14
15 HPPD, 4-hydroxyphenylpyruvate dioxygenase; *PfHPPD*, *Pseudomonas fluorescens* HPPD;
16
17 *ZmHPPD*, *Zea mais* HPPD; *AtHPPD*, *Arabidopsis thaliana* HPPD; *SaHPPD*, *Streptomyces*
18
19 *avermitilis* HPPD; *RnHPPD*, *Rattus norvegicus* HPPD; NTBC, 2-[2-nitro-4-
20
21 (trifluoromethyl)benzoyl]cyclohexane-1,3-dione, nitisinone; PAH, phenylalanine-4-hydroxylase;
22
23 FAH, fumarylacetoacetate hydrolase; HGD, homogentisate dioxygenase; HGA, homogentisic
24
25 acid; TAT, tyrosine aminotransferase; HPP, 4-hydroxyphenylpyruvate; MAAI,
26
27 maleylacetoacetate isomerase; UniProtKB, UniProt Knowledgebase database; PIR, Protein
28
29 Information Resource; MNPBQ, 2-methyl-6-nonaprenyl-1,4-benzoquinone; MPBQ, 2-methyl-6-
30
31 phytyl-1,4-benzoquinone; DMPBQ, 2,3-dimethyl-6-phytyl-1,4-benzoquinone; DKN, diketone
32
33 of isoxaflutole; PPDB, Pesticide Properties Database; TH, tyrosine hydroxylase, Tyr, tyrosine;
34
35 Phe, phenylalanine; T1T, type I tyrosinemia.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Lindstedt, S.; Holme, E.; Lock, E. A.; Hjalmarson, O.; Strandvik, B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. *Lancet* **1992**, *340*, 813-817.
2. Ashburn, T. T.; Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. *Nat. Rev. Drug Discov.* **2004**, *3*, 673-683.
3. Langedijk, J.; Mantel-Teeuwisse, A. K.; Slijkerman, D. S.; Schutjens, M. D. B. Drug repositioning and repurposing: terminology and definitions in literature. *Drug Discov. Today* **2015**, *20*, 1027-1034.
4. Nosengo, N. New tricks for old drugs. *Nature* **2016**, *534*, 314-316.
5. Lekka, E.; Deftereos, S. N.; Persidis, A.; Persidis, A.; Andronis, C. Literature analysis for systematic drug repurposing: a case study from Biovista. *Drug Discov. Today Ther. Strat.* **2011**, *8*, 103-108.
6. Iwata, H.; Sawada, R.; Mizutani, S.; Yamanishi, Y. Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data. *J. Chem. Inf. Model.* **2015**, *55*, 446-459.
7. Calder, A. N.; Androphy, E. J.; Hodgetts, K. J. Small molecules in development for the treatment of spinal muscular atrophy. *J. Med. Chem.* **2016**, *59*, 10067-10083.
8. Bhinder, B.; Djaballah, H. Drug discovery and repurposing at Memorial Sloan Kettering Cancer Center: chemical biology drives translational medicine. *ACS Chem. Biol.* **2014**, *9*, 1394-1397.
9. National center for advancing translational sciences. <https://ncats.nih.gov/preclinical/repurpose>, accessed August 18, 2016.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
10. Naylor, S.; Schonfeld, J. M. Therapeutic drug repurposing, repositioning and rescue. Part I: overview. *Drug Discov. World* **2015**, winter 2014/15, 49-62.
 11. Drug Repurposing, Rescue, and Repositioning. <http://www.liebertpub.com/overview/drug-repurposing-rescue-brand-repositioning/627>, accessed August 18, 2016.
 12. Drug repositioning, repurposing, and rescue conference. <http://www.drugrepositioningconference.com/index>, accessed August 18, 2016.
 13. Khedr, M. A.; Shehata, T. M.; Mohamed, M. E. Repositioning of 2,4-dichlorophenoxy acetic acid as a potential anti-inflammatory agent: *in silico* and pharmaceutical formulation study. *Eur. J. Pharm. Sci.* **2014**, *65*, 130-138.
 14. Lock, E. A.; Ellis, M. K.; Gaskin, P.; Robinson, M.; Auton, T. R.; Provan, W. M.; Smith, L. L.; Prisbylla, M. P.; Mutter, L. C.; Lee, D. L. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. *J. Inher. Metab. Dis.* **1998**, *21*, 498-506.
 15. Holme, E.; Lindstedt, S. Tyrosinaemia type I and NTBC 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione. *J. Inher. Metab. Dis.* **1998**, *21*, 507-517.
 16. Braconi, D.; Millucci, L.; Bernardini, G.; Santucci, A. Oxidative stress and mechanisms of ochronosis in alkaptonuria. *Free Radic. Biol. Med.* **2015**, *88*, 70-80.
 17. Moran, G. R. 4-Hydroxyphenylpyruvate dioxygenase. *Arch. Biochem. Biophys.* **2005**, *433*, 117-128.
 18. Moran, G. R. 4-Hydroxyphenylpyruvate dioxygenase and hydroxymandelate synthase: exemplars of the α -keto acid dependent oxygenases. *Arch. Biochem. Biophys.* **2014**, *544*, 58-68.
 19. Human 4-hydroxyphenylpyruvate dioxygenase, <http://www.uniprot.org/uniprot/P32754>, accessed August 5, 2016.

- 1
2
3 20. The Universal Protein Resource (UniProt), www.uniprot.org, accessed December 5, 2016.
- 4
5 21. Huang, C.; Liu, H.; Shen, C.; Chen, Y.; Lee, S.; Lloyd, M.; Lee, H. The different catalytic
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
22. Protein Information Resource, pir.georgetown.edu/pirwww/search/multialn.shtml, accessed
December 5, 2016.
23. Yang, C.; Pflugrath, J. W.; Camper, D. L.; Foster, M. L.; Pernich, D. J.; Walsh, T. A.
Structural basis for herbicidal inhibitor selectivity revealed by comparison of crystal structures of
plant and mammalian 4-hydroxyphenylpyruvate dioxygenases. *Biochemistry* **2004**, *43*, 10414-
10423.
24. Fritze, I. M.; Linden, L.; Freigang, J.; Auerbach, G.; Huber, R.; Steinbacher, S. The crystal
structures of *Zea mays* and *Arabidopsis* 4-hydroxyphenylpyruvate dioxygenase. *Plant Physiol.*
2004, *134*, 1388-1400.
25. Brownlee, J.; Johnson-Winters, K.; Harrison, D. H. T.; Moran, G. R. Structure of the ferrous
form of (4-hydroxyphenyl)pyruvate dioxygenase from *Streptomyces avermitilis* in complex with
the therapeutic herbicide, NTBC. *Biochemistry* **2004**, *43*, 6370-6377.
26. Serre, L.; Sailland, A.; Sy, D.; Boudec, P.; Rolland, A.; Pebay-Peyroula, E.; Cohen-Addad, C.
Crystal structure of *Pseudomonas fluorescens* 4-hydroxyphenylpyruvate dioxygenase: an enzyme
involved in the tyrosine degradation pathway. *Structure* **1999**, *7*, 977-988.
27. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I.
N.; Bourne, P. E. The Protein Data Bank. *Nucleic Acids Res.* **2000**, *28*, 235-242; www.rcsb.org.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28. Siddal, T. L.; Ouse, D. G.; Benko, Z. L.; Garvin, G. M.; Jackson, J. L.; McQuiston, J. M.; Ricks, M.J.; Thibault, T. D.; Turner, J. A.; VanHeertum, J. C.; Weimer, M. R. Synthesis and herbicidal activity of phenyl-substituted benzoylpyrazoles. *Pest Manag. Sci.* **2002**, *58*, 1175-1186.
29. Lin, J.; Sheih, Y.; Chang, T.; Chang, N.; Chang, C.; Shen, C.; Lee, H. The interactions in the carboxy terminus of human hydroxyphenylpyruvate dioxygenase are critical to mediate the conformation of the final helix and the tail to shield the active site for catalysis. *PLoS ONE* **2013**, *8*, e69733.
30. Kavana, M.; Moran, G. R. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. *Biochemistry* **2003**, *42*, 10238-10245.
31. Garcia, I.; Job, D.; Matringe, M. Inhibition of *p*-hydroxyphenylpyruvate dioxygenase by the diketonitrile of isoxaflutole: a case of half-site reactivity. *Biochemistry* **2000**, *39*, 7501-7507.
32. Discovery Studio 3.0 Visualizer, formerly distributed by Accelrys Software, Inc., now Dassault Systèmes Biovia, <http://accelrys.com/products/collaborative-science/biovia-discovery-studio/visualization.html>, accessed August 22, 2016.
33. Kaafarani, B. R.; Wex, B.; Oliver, A. G.; Krause Bauerc, J. A.; Neckersa, D. C. π - π -Stacking and nitro- π -stacking interactions of 1-(4-nitrophenyl)-4-phenyl-2,4-bis(phenylethynyl)butadiene. *Acta Cryst. Sect. E* **2003**, *E59*, o227-o229.
34. Borowski, T.; Bassan, A.; Siegbahn, P. E. M. 4-Hydroxyphenylpyruvate dioxygenase: a hybrid density functional study of the catalytic reaction mechanism. *Biochemistry* **2004**, *43*, 12331-12342.

- 1
2
3 35. Wojcik, A.; Broclawik, E.; Siegbahn, P. E. M.; Lundberg, M.; Moran, G.; Borowski, T. Role
4 of substrate positioning in the catalytic reaction of 4-hydroxyphenylpyruvate dioxygenase – a
5 QM/MM study. *J. Am. Chem. Soc.* **2014**, *136*, 14472-14485.
6
7
8
9
10 36. Molchanov, S.; Gryff-Keller, A. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-[2-
11 nitro-4-(trifluoromethyl)benzoyl]1,3-cyclohexanedione. *Acta Biochim. Pol.* **2009**, *56*, 447-454.
12
13
14 37. Raspail, C.; Graindorge, M.; Moreau, Y.; Crouzy, S.; Lefebvre, B.; Robin, A. Y.; Dumas, R.;
15 Matringe, M. 4-Hydroxyphenylpyruvate dioxygenase catalysis. Identification of catalytic
16 residues and production of a hydroxylated intermediate shared with a structurally unrelated
17 enzyme. *J. Biol. Chem.* **2011**, *286*, 26061-26070.
18
19
20 38. Gunsior, M.; Ravel, J.; Challis, G. L.; Townsend, C. A. Engineering *p*-
21 hydroxyphenylpyruvate dioxygenase to a *p*-hydroxymandelate synthase and evidence for the
22 proposed benzene oxide intermediate in homogentisate formation. *Biochemistry* **2004**, *43*, 663-
23 674.
24
25 39. Brownlee, J. M.; Heinz, B.; Bates, J.; Moran, G. R. Product analysis and inhibition studies of
26 a causative Asn to Ser variant of 4-hydroxyphenylpyruvate dioxygenase suggest a simple route to
27 the treatment of hawkinsinuria. *Biochemistry* **2010**, *49*, 7218-7226.
28
29 40. Diebold, A. R.; Brown-Marshall, C. D.; Neidig, M. L.; Brownlee, J. M.; Moran, G. R.;
30 Solomon, E. I. Activation of α -keto acid-dependent dioxygenases: application of an
31 $\{\text{FeNO}\}^7/\{\text{FeO}_2\}^8$ methodology for characterizing the initial steps of O_2 activation. *J. Am. Chem.*
32 *Soc.* **2011**, *133*, 18148-18160.
33
34 41. Hawkes, T. R. Hydroxyphenylpyruvate dioxygenase (HPPD): the herbicide target. In *Modern*
35 *Crop Protection Compounds, Second Edition, Chapter 4: Herbicides with bleaching properties*;

1
2
3 Kramer, W., Schirmer, U., Jeschke, P., Witschel, M., Eds.; Wiley-VCH Verlag GmbH & Co.
4
5 KgaA: Weinheim, Germany, 2012; pp 225-235.
6

7
8 42. Cheng, Z.; Sattler, S.; Maeda, H.; Sakuragi, Y.; Bryant, D. A.; DellaPenna, D. Highly
9
10 divergent methyltransferases catalyze a conserved reaction in tocopherol and plastoquinone
11
12 synthesis in cyanobacteria and photosynthetic eukaryotes. *Plant Cell* **2003**, *15*, 2343-2356.
13

14
15 43. Norris, S. R.; Barrette, T. R.; DellaPenna, D. Genetic dissection of carotenoid synthesis in
16
17 arabidopsis defines plastoquinone as an essential component of phytoene desaturation. *Plant Cell*
18
19 **1995**, *7*, 2139-2149.
20

21
22 44. Rosa, A.; Tuberoso, C. I. G.; Atzeri, A.; Melis, M. P.; Bifulco, E.; Dessì, M. A. Antioxidant
23
24 profile of strawberry tree honey and its marker homogentisic acid in several models of oxidative
25
26 stress. *Food Chem.* **2011**, *129*, 1045-1053.
27

28
29 45. Wang, H.; Qiao, Y.; Chai, B.; Qiu, C.; Chen, X. Identification and molecular characterization
30
31 of the homogentisate pathway responsible for pyomelanin production, the major melanin
32
33 constituents in *Aeromonas media* WS. *PLoS ONE* **2015**, *10*, e0120923.
34

35
36 46. Roberts, N. B.; Curtis, S. A.; Milan, A. M.; Ranganath, L. R. The pigment in alkaptonuria
37
38 relationship to melanin and other coloured substances: a review of metabolism, composition and
39
40 chemical analysis. *J. Inherit. Metab. Dis.* **2015**, *24*, 51-66.
41

42
43 47. Solano, F. Melanins: skin pigments and much more – types, structural models, biological
44
45 functions, and formation routes. *New J. Sci.* **2014**, *2014*, 498276.
46

47
48 48. Lindstedt, S.; Rundgren, M. Inhibition of 4-hydroxyphenylpyruvate dioxygenase from
49
50 *Pseudomonas* sp. strain P.J. 874 by the *enol* tautomer of the substrate. *Biochim. Biophys. Acta*
51
52 **1982**, *704*, 66-74.
53
54
55
56
57
58
59
60

- 1
2
3
4 49. Dayan, F. E.; Duke, S. O.; Sauldubois, A.; Singh, N.; McCurdy, C.; Cantrell, C. *p*-
5
6 Hydroxyphenylpyruvate dioxygenase is a herbicidal target site for β -triketones from
7
8 *Leptospermum scoparium*. *Phytochemistry* **2007**, *68*, 2004-2014.
9
10
11 50. Ellis, M. K. ; Whitfield, A. C.; Gowans, L. A.; Auton, T. R.; McLean Provan, W.; Lock, E.
12
13 A.; Smith, L. L. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-
14
15 trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-
16
17 cyclohexane-1,3-dione. *Toxicol. Appl. Pharmacol.* **1995**, *133*, 12-19.
18
19
20 51. Ellis, M. K.; Whitfield, A. C.; Gowans, L. A.; Auton, T. R.; McLean Provan, W.; Lock, E.
21
22 A.; Lee, D. L.; Smith, L. L. Characterization of the interaction of 2-[2-nitro-4-
23
24 (trifluoromethyl)benzoyl]-4,4,6,6-tetramethyl-cyclohexane-1,3,5-trione with rat hepatic 4-
25
26 hydroxyphenylpyruvate dioxygenase. *Chem. Res. Toxicol.* **1996**, *9*, 24-27.
27
28
29 52. Laschi, M.; Bernardini, G.; Dreassi, E.; Millucci, L.; Geminiani, M.; Braconi, D.; Marzocchi,
30
31 B.; Botta, M.; Manetti, F.; Santucci, A. Inhibition of *para*-hydroxyphenylpyruvate dioxygenase
32
33 by analogues of the herbicide nitisinone as a strategy to decrease homogentisic acid levels, the
34
35 causative agent of alkaptonuria. *ChemMedChem* **2016**, *11*, 674-678.
36
37
38 53. Copeland, R. A. The drug-target residence time model: a 10-year retrospective. *Nat. Rev.*
39
40 *Drug Discov.* **2016**, *15*, 87-95.
41
42
43 54. Mitchell, G.; Bartlett, D. W.; Fraser, T. E. M.; Hawkes, T. R.; Holt, D. C.; Townson, J. K.;
44
45 Wichert, R. A. Mesotrione: a new selective herbicide for use in maize. *Pest Manag. Sci.* **2001**, *57*,
46
47 120-128.
48
49
50 55. Siehl, D. L.; Tao, Y.; Albert, H.; Dong, Y.; Heckert, M.; Madrigal, A.; Lincoln-Cabatu, B.;
51
52 Lu, J.; Fenwick, T.; Bermudez, E.; Sandoval, M.; Horn, C.; Green, J. M.; Hale, T.; Pagano, P.;
53
54 Clark, J.; Udranszky, I. A.; Rizzo, N.; Bourett, T.; Howard, R. J.; Johnson, D. H.; Vogt, M.;
55
56
57
58
59
60

- 1
2
3 Akinsola, G.; Castle, L. A. Broad 4-hydroxyphenylpyruvate dioxygenase inhibitor herbicide
4 tolerance in soybean with an optimized enzyme and expression cassette. *Plant Physiol.* **2014**, *166*,
5 1162-1176.
6
7
8
9
10 56. Ahrens, H.; Lange, G.; Muller, T.; Rosinger, C.; Willms, L.; van Almsick, A. 4-
11 Hydroxyphenylpyruvate dioxygenase inhibitors in combination with safeners: solutions for
12 modern and sustainable agriculture. *Angew. Chem. Int. Ed.* **2013**, *52*, 9388-9398.
13
14
15 57. Witschel, M. Design, synthesis and herbicidal activity of new iron chelating motifs for
16 HPPD-inhibitors. *Bioorg. Med. Chem.* **2009**, *17*, 4221-4229.
17
18
19
20 58. Kraehmer, H.; van Almsick, A.; Beffa, R.; Dietrich, H.; Eckes, P.; Hacker, E.; Hain, R.; Streck,
21 H. J.; Stuebler, H.; Willms, L. Herbicides as weed control agents: state of the art: II. Recent
22 achievements. *Plant Physiol.* **2014**, *166*, 1132-1148.
23
24
25 59. U.S. environmental protection agency, office of pesticide programs, registration division,
26 https://www3.epa.gov/pesticides/chem_search/ppls/000100-01467-20150424.pdf,
27 accessed
28 December 2, 2016.
29
30
31 60. Jeanmart, S.; Edmunds, A. J. F.; Lamberth, C.; Pouliot, M. Synthetic approaches to the 2010-
32 2014 new agrochemicals. *Bioorg. Med. Chem.* **2016**, *24*, 317-341.
33
34
35 61. Heap, I. The International survey of herbicide resistant weeds.
36 <http://www.weedscience.org/Summary/MOA.aspx?MOAID=10>, accessed July 26, 2016.
37
38
39 62. Matsumoto, H. Mode of action of pyrazole herbicides pyrazolate and pyrazoxyfen: HPPD
40 inhibition by the common metabolite. In *New discoveries in agrochemicals*; Clark, J. M., Ohkawa,
41 H., Eds.; American Chemical Society: Washington DC, 2004; pp 161-171.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 63. Shimoharada, H.; Tsukamoto, M.; Ikeguchi, M.; Kikugawa, H.; Sano, M.; Kitahara, Y.;
4
5 Kominami, H.; Okita, T. Benzoylpyrazole compounds and herbicides containing them. WO
6
7 2007/069771, June 21, 2007.
8
9
10 64. Williams, K. L.; Tjeerdema, R. S. Hydrolytic activation kinetics of the herbicide
11
12 benzobicyclon in simulated aquatic systems. *J. Agric. Food Chem.* **2016**, *64*, 4838-4844.
13
14 65. Komatsubara, K.; Sekino, K.; Yamada, Y.; Koyanagi, H.; Nakahara, S. Discovery and
15
16 development of a new herbicide, benzobicyclon. *J. Pestic. Sci.* **2009**, *34*, 113-114.
17
18 66. Pallett, K. E.; Cramp, S. M.; Little, J. P.; Veerasekaran, P.; Crudace, A. J.; Slater, A. E.
19
20 Isoxaflutole: the background of its discovery and the basis of its herbicidal properties. *Pest*
21
22 *Manag. Sci.* **2001**, *57*, 133-142.
23
24 67. Knudsen, C. G.; Lee, D. L.; Michaely, W. J.; Chin, H.-L.; Nguyen, N. H.; Rusay, R. J.;
25
26 Cromartie, T. H.; Gray, R.; Lake, B. H.; Fraser, T. E. M.; Cartwright, D. Discovery of the
27
28 triketone class of HPPD inhibiting herbicides and their relationship to naturally occurring β -
29
30 triketones. In *Allelopathy in ecological agriculture and forestry. Proceedings of the III*
31
32 *international congress on allelopathy in ecological agriculture and forestry*; Narwal, S. S.,
33
34 Hoagland, R. E., Dilday, R. H., Reigosa, M. J., Eds.; Kluwer Academic Publishers: Dordrecht,
35
36 the Netherlands, 2000; pp 101-111.
37
38 68. Penfold, A. R. On the occurrence of a new phenol in the essential oils of the "Leptospermum".
39
40 *J. Proc. Royal Soc. New South Wales* **1921**, *55*, 49-51.
41
42 69. Owens, D. K.; Nanayakkara, N. P.; Dayan, F. E. *In planta* mechanism of action of
43
44 leptospermone: impact of its physico-chemical properties on uptake, translocation, and
45
46 metabolism. *J. Chem. Ecol.* **2013**, *39*, 262-270.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 70. Porter, N. G.; Wilkins, A. L. Chemical, physical and antimicrobial properties of essential oils
4 of *Leptospermum scoparium* and *Kunzea ericoides*. *Phytochemistry* **1998**, *50*, 407-415.
5
6
7
8 71. Dayan, F. E.; Singh, N.; McCurdy, C.; Godfrey, C. A.; Larsen, L.; Weavers, R. T.; van Klink,
9 J. W.; Perry, N. B. β -Triketones inhibitors of plant *p*-hydroxyphenylpyruvate dioxygenase:
10 modeling and comparative molecular field analysis of their interactions. *J. Agric. Food Chem.*
11 **2009**, *57*, 5194-5200.
12
13
14
15
16
17 72. Lee, D. L.; Knudsen, C. G.; Michaely, W. J.; Chin, H.-L.; Nguyen, N. H.; Carter, C. G.;
18 Cromartie, T. H.; Lake, B. H.; Shribbs, J. M.; Fraser, T. The structure-activity relationships of the
19 triketon class of HPPD herbicides. *Pestic. Sci.* **1998**, *54*, 377-384.
20
21
22
23
24
25 73. Beaudegnies, R.; Edmunds, A. J. F.; Fraser, T. E. M.; Hall, R. G.; Hawkes, T. R.; Mitchell,
26 G.; Schaetzer, J.; Wendeborn, S.; Wibley, J. Herbicidal 4-hydroxyphenylpyruvate dioxygenase
27 inhibitors – a review of the triketone chemistry story from a Syngenta perspective. *Bioorg. Med.*
28 *Chem.* **2009**, *17*, 4134-4152.
29
30
31
32
33
34 74. Sandmann, G.; Boger, P.; Kumita, I. Atypical inhibition of phytoene desaturation by 2-(4-
35 chloro-2-nitrobenzoyl)-5,5-dimethylcyclohexane-1,3-dione. *Pestic. Sci.* **1990**, *30*, 353-355.
36
37
38
39 75. Lee, D. L.; Prysbylla, M. P.; Cromartie, T. H.; Dagarin, D. P.; Howard, S. W.; McLean
40 Provan, W.; Ellis, M. K.; Fraser, T.; Mutter, L. C. The discovery and structural requirements of
41 inhibitors of *p*-hydroxyphenylpyruvate dioxygenase. *Weed Sci.* **1997**, *45*, 601-609.
42
43
44
45
46 76. Edmunds, A. J. F.; Morris, J. A. Triketones. In *Modern Crop Protection Compounds, Second*
47 *Edition, Chapter 4: Herbicides with bleaching properties*; Kramer, W., Schirmer, U., Jeschke, P.,
48 Witschel, M., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2012; pp 235-
49
50
51
52
53 262.
54
55
56
57
58
59
60

- 1
2
3 77. Wu, C.; Huang, J.; Sun, Y.; Yang, D. Mode of action of 4-hydroxyphenylpyruvate
4 dioxxygenase inhibition by triketone-type inhibitors. *J. Med. Chem.* **2002**, *45*, 2222-2228.
5
6
7
8 78. Huang, M.-L.; Zou, J.-W.; Yang, D.-Y.; Ning, B.-Z.; Shang, Z.-C.; Yu, Q.-S. Theoretical
9 studies on tautomerism of benzoylcyclohexane-1,3-dione and its derivatives. *J. Mol. Struct.*
10 (*Teochem*) **2002**, *589-590*, 321-328.
11
12
13 79. Wu, N.; Jin, Y.; Jin, F.; Tan, Y.; Tao, H.; Zheng, M.; Chen, R.; Liu, K.; Gao, M. Effects of
14 sulcotrione [2-(2-chloro-4-mesybenzoyl)-cyclohexane-1,3-dione] on enzymes involved in
15 tyrosine catabolism and the extent of the resulting tyrosinemia and its relationship with corneal
16 lesions in rats. *Pestic Biochem. Physiol.* **2011**, *99*, 162-169.
17
18
19
20 80. Lin, Y.; Wu, C.; Lin, S.; Yang, D. SAR studies of 2-*o*-substituted-benzoyl- and 2-alkanoyl-
21 cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxxygenase. *Bioorg. Med.*
22 *Chem. Lett.* **2000**, *10*, 843-845.
23
24
25 81. Kuo, P.; Shie, T.; Chen, Y.; Lai, J.; Yang, D. Enzyme inhibition potency enhancement by
26 active site metal chelating and hydrogen bonding induced conformation-restricted
27 cyclopropanecarbonyl derivatives. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 6024-6027.
28
29
30 82. Lin, S.; Lin, Y.; Lin, T.; Yang, D. Discovery of a potent, non-triketone type inhibitor of 4-
31 hydroxyphenylpyruvate dioxxygenase. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1297-1298.
32
33
34 83. Lin, Y.; Wu, C.; Lin, S.; Huang, J.; Sun, Y.; Yang, D. SAR studies of 3-
35 cyclopropanecarbonyloxy-2-cyclohexen-1-one as inhibitors of 4-hydroxyphenylpyruvate
36 dioxxygenase. *Bioorg. Med. Chem.* **2002**, *10*, 685-690.
37
38
39 84. Huang, J.; Liu, H.; Yang, D. Acylcyclohexanedione derivatives as potential in vivo sequential
40 inhibitors of 4-hydroxyphenylpyruvate dioxxygenase and GA₂₀ 3 β -hydroxylase. *Bioorg. Med.*
41 *Chem. Lett.* **2003**, *13*, 927-930.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 85. Wang, D.; Lin, H.; Cao, R.; Ming, Z.; Chen, T.; Hao, G.; Yang, W.; Yang, G. Design,
4 synthesis and herbicidal activity of novel quinazoline-2,4-diones as 4-hydroxyphenylpyruvate
5 dioxxygenase inhibitors. *Pest Manag. Sci.* **2015**, *71*, 1122-1132.
6
7
8
9
10 86. Wang, D.; Lin, H.; Cao, R.; Yang, S.; Chen, Q.; Hao, G.; Yang, W.; Yang, G. Synthesis and
11 herbicidal evaluation of triketone-containing quinazoline-2,4-diones. *J. Agric. Food Chem.* **2014**,
12 *62*, 11786-11796.
13
14
15
16
17 87. Wang, D.; Lin, H.; Cao, R.; Chen, T.; Wu, F.; Hao, G.; Yang, W.; Yang, G. Synthesis and
18 herbicidal activity of triketone-quinoline hybrids as novel 4-hydroxyphenylpyruvate dioxxygenase
19 inhibitors. *J. Agric. Food Chem.* **2015**, *63*, 5587-5596.
20
21
22
23
24 88. Wang, D.-W.; Lin, H.-Y.; He, B.; Wu, F.-X.; Chen, T.; Chen, Q.; Yang, W.-C.; Yang, G.-F.
25 An efficient one-pot synthesis of 2-(aryloxyacetyl)cyclohexane-1,3-diones as herbicidal 4-
26 hydroxyphenylpyruvate dioxxygenase inhibitors. *J. Agric. Food Chem.* **2016**, *64*, 8986–8993.
27
28
29
30
31 89. Grossmann, K.; Ehrhardt, T. On the mechanism of action and selectivity of the corn herbicide
32 topramezone: a new inhibitor of 4-hydroxyphenylpyruvate dioxxygenase. *Pest Manag. Sci.* **2007**,
33 *63*, 429-429.
34
35
36
37
38 90. Xu, Y.; Lin, H.; Cao, R.; Ming, Z.; Yang, W.; Yang, G. Pyrazolone-quinazolone hybrids: a
39 novel class of human 4-hydroxyphenylpyruvate dioxxygenase inhibitors. *Bioorg. Med. Chem.*
40 **2014**, *22*, 5194-5211.
41
42
43
44
45 91. Xu, Y.; Lin, H.; Ruan, X.; Yang, S.; Hao, G.; Yang W.; Yang, G. Synthesis and bioevaluation
46 of pyrazole-benzimidazolone hybrids as novel human 4-hydroxyphenylpyruvate dioxxygenase
47 inhibitors. *Eur. J. Med. Chem.* **2015**, *92*, 427-438.
48
49
50
51 92. Claisen, L.; Stock, R. Ueber die einwirkung des hydroxylamins ouf den benzoylaldehyd
52 $C_6H_5-CO-CH_2-COH$. *Ber. Dtsch. Chem. Ges.* **1891**, *24*, 130-138.
53
54
55
56
57
58
59
60

- 1
2
3 93. van Almsick, A. Hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors: heterocycles. In
4
5 *Modern Crop Protection Compounds, Second Edition, Chapter 4: Herbicides with bleaching*
6
7 *properties*; Kramer, W., Schirmer, U., Jeschke, P., Witschel, M., Eds.; Wiley-VCH Verlag
8
9 GmbH & Co. KgaA: Weinheim, Germany, 2012; pp 262-276.
- 10
11
12 94. Lei, K.; Hua, X.-W.; Tao, Y.-Y.; Liu, Y.; Liu, N.; Ma, Y.; Li, Y.-H.; Xu, X.-H.; Kong, C.-H.
13
14 Discovery of (2-benzoylolefin-1-ol)-containing 1,2-benzothiazine derivatives as novel 4-
15
16 hydroxyphenylpyruvate dioxygenase (HPPD) inhibiting-based herbicide lead compounds. *Bioorg.*
17
18 *Med. Chem.* **2016**, *24*, 92-103.
- 19
20
21 95. Romagni, J. G.; Meazza, G.; Nanayakkara, N. P. D.; Dayan, F. E. The phytotoxic lichen
22
23 metabolite, usnic acid, is a potent inhibitor of plant *p*-hydroxyphenylpyruvate dioxygenase. *FEBS*
24
25 *Lett.* **2000**, *480*, 301-305.
- 26
27
28 96. Romagni, J. G.; Rosell, R. C.; Nanayakkara, N. P. D.; Dayan, F. E. Ecophysiology and
29
30 potential mode of action for selected lichen secondary metabolites. In *Allelopathy: chemistry and*
31
32 *mode of action of allelochemicals*; Macias, F. A., Galindo, J. C. G., Molinillo, J. M. G., Cutler, H.
33
34 G., Eds.; CRC Press LLC: Boca Raton, FL, 2000; pp 13-33.
- 35
36
37 97. Meazza, G.; Scheffler, B. E.; Tellez, M. R.; Rimando, A. M.; Romagni, J. G.; Duke, S. O.;
38
39 Nanayakkara, D.; Khan, I. A.; Abourashed, E. A.; Dayan, F. E. The inhibitory activity of natural
40
41 products on plant *p*-hydroxyphenylpyruvate dioxygenase. *Phytochemistry* **2002**, *59*, 281-288.
- 42
43
44 98. Chiari, M. E.; Tosoni, L.; Joray, M. B.; Diaz Napal, G. N.; Palacios, S. M.; Ruiz, G. M.; Vera,
45
46 D. M. A.; Carpinella, M. C. The inhibitory activity of plants from central Argentina on *p*-
47
48 hydroxyphenylpyruvate dioxygenase. Isolation and mechanism of inhibition of a flavanone from
49
50 *Flourensia oolepis*. *Planta Med.* **2015**, *81*, 1382-1391.
- 51
52
53
54
55
56
57
58
59
60

- 1
2
3 99. Ling, T.; Shiu, S.; Yang, D. Design and synthesis of 3-fluoro-2-oxo-3-phenylpropionic acid
4 derivatives as potent inhibitors of 4-hydroxyphenylpyruvate dioxygenase from pig liver. *Bioorg.*
5
6 *Med. Chem.* **1999**, *7*, 1459-1465.
7
8
9
10 100. Sergeant, M. J.; Harrison, P. J.; Jenkins, R.; Moran, G. R.; Bugg, T. D. H.; Thompson, A. J.
11
12 Phytotoxic effects of selected *N*-benzyl-benzoylhydroxamic acid metallo-oxygenase inhibitors:
13
14 investigation into mechanism of action. *New J. Chem.* **2013**, *37*, 3461-3465.
15
16
17 101. Lopez-Ramos, M.; Perruccio, F. HPPD: ligand- and target-based virtual screening on a
18
19 herbicide target. *J. Chem. Inf. Model.* **2010**, *50*, 801-814.
20
21
22 102. Cho, J. E.; Kin, J. T.; Kim, E.; Ko, Y. K.; Kang, N. S. The structure-based three-dimensional
23
24 pharmacophore models for *Arabidopsis thaliana* HPPD inhibitors as herbicide. *Bull. Korean*
25
26 *Chem. Soc.* **2013**, *34*, 2909-2914.
27
28
29 103. Gomez-Jeria, J. S.; Moreno-Rojas, C. A theoretical study of the inhibition of human 4-
30
31 hydroxyphenylpyruvate dioxygenase by a series of pyrazalone-quinazolone hybrids. *Pharma*
32
33 *Chem.* **2016**, *8*, 475-482.
34
35
36 104. Cardoso Silva, T.; dos Santos Pires, M.; Alves de Castro, A.; da Cunha, E. F. F.; Soares
37
38 Caetano, M.; Ramalho, T. C. Molecular insight into the inhibition mechanism of plant and rat 4-
39
40 hydroxyphenylpyruvate dioxygenase by molecular docking and DFT calculations. *Med. Chem.*
41
42 *Res.* **2015**, *24*, 3958-3971.
43
44
45 105. Natt, E.; Kida, K.; Odievre, M.; Di Rocco, M.; Scherer, G. Point mutations in the tyrosine
46
47 aminotransferase gene in tyrosinemia type II. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, *89*, 9297-9301.
48
49
50 106. Angileri, F.; Bergeron, A.; Morrow, G.; Lettre, F.; Gray, G.; Hutchin, T.; Ball, S.; Tanguay,
51
52 R. M. Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase
53
54 gene in hereditary tyrosinemia type 1. *J. Inher. Metab. Dis. Rep.* **2015**, *19*, 43-58.
55
56
57
58
59
60

- 1
2
3 107. Jorquera, R.; Tanguay, R. M. Fumarylacetoacetate, the metabolite accumulating in
4 hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and
5 genomic instability. *Hum. Mol. Genet.* **2001**, *10*, 1741-1752.
6
7
8
9
10 108. Geminiani, M.; Gambassi, S.; Millucci, L.; Lupetti, P.; Collodel, G.; Mazzi, L.; Frediani, B.;
11 Braconi, D.; Mazzocchi, B.; Laschi, M.; Bernardini, G.; Santucci, A. Cytoskeleton aberrations in
12 alkaptonuric chondrocytes. *J. Cell Physiol.* [Accepted manuscript online]. DOI:
13 10.1002/jcp.25500. Published Online: July 25, 2016.
14
15
16
17
18 109. Millucci, L.; Giorgetti, G.; Viti, C.; Ghezzi, L.; Gambassi, S.; Braconi, D.; Marzocchi, B.;
19 Paffetti, A.; Lupetti, P.; Bernardini, G.; Orlandini, M.; Santucci, A. Chondroptosis in
20 alkaptonuric cartilage. *J. Cell Physiol.* **2015**, *230*, 1148-1157.
21
22
23
24
25 110. Braconi, D.; Bernardini, G.; Bianchini, C.; Laschi, M.; Millucci, L.; Amato, L.; Tinti, L.;
26 Serchi, T.; Chellini, F.; Spreafico, A.; Santucci, A. Biochemical and proteomic characterization of
27 alkaptonuric chondrocytes. *J. Cell Physiol.* **2012**, *227*, 3333-3343.
28
29
30
31
32 111. Laschi, M.; Tinti, L.; Braconi, D.; Millucci, L.; Ghezzi, L.; Amato, L.; Selvi, E.; Spreafico,
33 A.; Bernardini, G.; Santucci, A. Homogentisate 1,2 dioxygenase is expressed in human
34 osteoarticular cells: implications in alkaptonuria. *J. Cell Physiol.* **2012**, *227*, 3254-3257.
35
36
37
38 112. Millucci, L.; Ghezzi, L.; Paccagnini, E.; Giorgetti, G.; Viti, C.; Braconi, D.; Laschi, M.;
39 Geminiani, M.; Soldani, P.; Lupetti, P.; Orlandini, M.; Benvenuti, C.; Perfetto, C.; Spreafico, A.;
40 Bernardini, G.; Santucci, A. Amyloidosis, inflammation, and oxidative stress in the heart of an
41 alkaptonuric patient. *Mediat. Inflamm.* **2014**, 258471.
42
43
44
45
46 113. Millucci, L.; Ghezzi, L.; Braconi, D.; Laschi, M.; Geminiani, M.; Amato, L.; Orlandini, M.;
47 Benvenuti, C.; Bernardini, G.; Santucci, A. Secondary amyloidosis in an alkaptonuric aortic
48 valve. *Int. J. Cardiol.* **2014**, *172*, e121-e123.
49
50
51
52
53
54
55
56
57
58
59
60



- 1
2
3 114. Bernardini, G.; Laschi, M.; Geminiani, M.; Braconi, D.; Vannuccini, E.; Lupetti, P.; Manetti,
4 F.; Millucci, L.; Santucci, A. Homogentisate 1,2 dioxygenase is expressed in brain: implications
5 in alkaptonuria. *J. Inherit. Metab. Dis.* **2015**, *38*, 807-14.
6
7
8
9
10 115. Wolff, F.; Biaou, I.; Koopmansch, C.; Vanden Bossche, M.; Pozdzik, A.; Roumeguère, T.;
11 Cotton, F. Renal and prostate stones composition in alkaptonuria: a case report. *Clin. Nephrol.*
12 **2015**, *84*, 339-342.
13
14
15
16
17 116. ClinicalTrials.gov, a service of the U. S. National Institutes of Health.
18 <https://clinicaltrials.gov/ct2/results?term=alkaptonuria+nitisinone&Search=Search>, accessed
19 August 25, 2016.
20
21
22
23
24 117. Lewis, R. W.; Botham, J. W. A review of the mode of toxicity and relevance to humans of
25 the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-1,3-cyclohexanedione. *Crit. Rev.*
26 *Toxicol.* **2013**, *43*, 185-199.
27
28
29
30
31 118. Lock, E. A.; Gaskin, P.; Ellis, M. K.; McLean Provan, W.; Robinson, M.; Smith, L. L.
32 Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) and
33 its effect on enzymes involved in tyrosine catabolism in the mouse. *Toxicology* **2000**, *144*, 179-
34 197.
35
36
37
38
39 119. Lock, E. A.; Gaskin, P.; Ellis, M.; Provan, W. M.; Smith, L. L. Tyrosinemia produced by 2-
40 (2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and
41 its relationship to corneal injury. *Toxicol. Appl. Pharmacol.* **2006**, *215*, 9-16.
42
43
44
45
46 120. Gamelin, L.; Turcant, A.; Ganiere-Monteil, C.; Harry, P. Toxicité des tricétones: rapport de
47 2 cas d'intoxication à la sulcotrione du Cap d'Angers et revue de la littérature. *Infotox Bull. Soc.*
48 *Toxicol. Clin.* **2006**, *23*, 3-6.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 121. Boels, D.; Ganiere-Monteil, C.; Turcant, A.; Bretaudeau, M.; Harry, P. Triketone toxicity: a
4 report on two cases of sulcotrione poisoning. *Hum. Exp. Toxicol.* **2013**, *32*, 778-782.
5
6
7
8 122. Hall, M. G.; Wilks, M. F.; McLean Provan, W.; Eksborg, S.; Lumholtz, B.
9 Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-
10 cyclohexanedione) and meotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD)
11 following a single dose to healthy male volunteers. *Br. J. Clin. Pharmacol.* **2001**, *52*, 169-177.
12
13
14
15 123. Lock, E.; Ranganath, L. R.; Timmis, O. The role of nitisinone in tyrosine pathway disorders.
16
17
18
19
20
21
22
23 124. Davison, A. S.; Milan, A. M.; Gallagher, J. A.; Ranganath, L. R. Acute fatal metabolic
24 complications in alkaptonuria. *J. Inherit. Metab. Dis.* **2016**, *39*, 203-210.
25
26
27 125. European Food Safety Authority. Conclusion on the peer review of the pesticide risk
28 assessment of the active substance tembotrione. *EFSA J.* **2013**, *11*, 3131.
29
30
31
32 126. Zunec, S.; Kasuba, V.; Pavicic, I.; Marjanovic, A. M.; Tariba, B.; Milic, M.; Kopjar, N.;
33 Pizent, A.; Vrdoljak, A. L.; Rozgaj, R.; Zeljezic, D. Assessment of oxidative stress responses and
34 the cytotoxic and genotoxic potential of the herbicide tembotrione in HepG2 cells. *Food Chem.*
35
36
37
38
39
40
41 127. Batisson, I.; Crouzet, O.; Besse-Hoggan, P.; Sancelme, M.; Mangot, J.-F.; Mallet, C.;
42 Bohatier, J. Isolation and characterization of mesotrione-degrading *Bacillus* sp. from soil.
43
44
45
46
47
48
49 128. Romdhane, S.; Devers-Lamrani, M.; Calvayrac, C.; Rocaboy-Faquet, E.; Riboul, D.; Cooper,
50 J. F.; Barthelmebs, L. Isolation and characterization of *Bradyrhizobium* sp. SR1 degrading two β -
51 triketone herbicides. *Environ. Sci. Pollut. Res. Int.* **2016**, *23*, 4138-4148.
52
53
54
55
56
57
58
59
60



- 1
2
3 129. Antonenko, A. M.; Blagaia, A. V.; Omelchuck, S. T.; Korshun, M. M.; Vavrinevych, H. P.;
4
5 Milohov, D. S.; Pelo, I. M.; Bojar, I. Mechanism of action of 4-hydroxyphenylpyruvate
6
7 dioxxygenase inhibitor herbicide on homoterm animals and humans. *J. Pre-Clin. Clin. Res.* **2015**,
8
9 *9*, 145-150.
- 10
11
12 130. Lewis, K. A.; Tzilivakis, J.; Warner, D.; Green, A. An international database for pesticide
13
14 risk assessments and management. *Hum. Ecol. Risk Assess.* **2016**, *22*, 1050-1064.
15
16 <http://sitem.herts.ac.uk/aeru/ppdb/en/index.htm>, accessed August 12, 2016.
17
18
19
20 131. Moran, G. R.; He, P. Treatment of microbial infections with compounds that inhibit 4-
21
22 hydroxyphenylpyruvate dioxxygenase. US 2010/227936 A1, September 9, 2010.
23
24
25 132. Christoph, F.; Kaulfers, P.-M.; Stahl-Biskup, E. A comparative study of the *in vitro*
26
27 antimicrobial activity of tea tree oils *s.l.* with special reference to the activity of β -triketones.
28
29 *Planta Med.* **2000**, *66*, 556-560.
30
31
32 133. van Klink, J. W.; Larsen, L.; Perry, N. B.; Weavers, R. T.; Cook, G. M.; Bremer, P. J.;
33
34 MacKenzie, A. D.; Kirikae, T. Triketones active againts antibiotic-resistant bacteria: synthesis,
35
36 structure-activity relationships, and mode of action. *Bioorg. Med. Chem.* **2005**, *13*, 6651-6662.
37
38
39 134. Reichling, J.; Koch, C.; Stahl-Biskup, E.; Sojka, C.; Schnitzler, P. Virucidal activity of a β -
40
41 triketone-rich essential oil of *Leptospermum scoparium* (Manuka oil) against HSV-1 and HSV-2
42
43 in cell culture. *Planta Med.* **2005**, *71*, 1123-1127.
44
45
46 135. Carroll, A. R.; Avery, V. M.; Duffy, S.; Forster, P. I.; Guymer, G. P. Watsonianone A-C,
47
48 anti-plasmodial β -triketones from the Australian tree, *Corymbia watsoniana*. *Org. Biomol. Chem.*
49
50 **2013**, *11*, 453-458.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 136. Sterkel, M.; Perdomo, H. D.; Guizzo, M. G.; Barletta, A. B. F.; Nunes, R. D.; Dias, F. A.;
4
5 Sorgine, M. H. F.; Oliveira, P. L. Tyrosine detoxification is an essential trait in the life history of
6
7 blood-feeding arthropods. *Curr. Biol.* **2016**, *26*, 2188–2193.
8
9
10 137. Travis, K. Z.; Posner, J. Use of HPPD inhibitors in the treatment of depression and/or
11
12 withdrawal symptoms associated with addictive drugs. WO 2008/020150, February, 21, 2008.
13
14 138. Pickford, L.; Meya, U.; Moran, M. Treatment of restless leg syndrome and sleep disorders.
15
16 WO 2010/54273, May 14, 2010.
17
18 139. Doe, J. E.; Sturgess, N. C.; Travis, K. Z. Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-
19
20 cyclohexanedione in the treatment of Parkinson's disease. WO 2006/090177, August 31, 2006.
21
22
23 140. Biotie therapies corp. Stock exchange release. 23 November 2011,
24
25 [http://www.biotie.com/investors/releases/pr-](http://www.biotie.com/investors/releases/pr-story.aspx?ResultPageURL=http://cws.huginonline.com/B/132030/PR/201111/1565991.xml)
26
27 [story.aspx?ResultPageURL=http://cws.huginonline.com/B/132030/PR/201111/1565991.xml](http://www.biotie.com/investors/releases/pr-story.aspx?ResultPageURL=http://cws.huginonline.com/B/132030/PR/201111/1565991.xml),
28
29 accessed August 17, 2016
30
31
32
33 141. Nitisinone for type 1B oculocutaneous albinism,
34
35 <https://clinicaltrials.gov/ct2/show/NCT01838655>, accessed August 18, 2016.
36
37
38 142. Onojafe, K. F.; Adams, D. R.; Simeonov, D. R.; Zhang, J.; Chan, C.; Bernardini, I. M.;
39
40 Sergeev, Y. V.; Dolinska, M. B.; Alur, R. P.; Brilliant, M. H.; Gahl, W. A.; Brooks, B. P.
41
42 Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous
43
44 albinism. *J. Clin. Invest.* **2011**, *121*, 3914–3923.
45
46
47 143. Brooks, B. P.; Gahl, W. A. The nitisinone for the treatment of oculocutaneous/ocular
48
49 albinism and for increasing pigmentation. WO 2011/106655, September 1, 2011.
50
51
52 144. Manga, P.; Orlow, S. J. Informed reasoning: repositioning of nitisinone to treat
53
54 oculocutaneous albinism. *J. Clin. Invest.* **2011**, *121*, 3828–3831.
55
56
57
58
59
60



Table 2. Structures of HPPD and its complexes stored in the protein data bank.

PDB entry ^a	Release date	Organism/Expression system	Chain: Solved sequence ^b	Ligand Cofactor Coordination	Binding mode ^c
5EC3	2015-11-18	<i>H. sapiens</i> <i>E. coli</i> BL21-Gold(DE3)pLysS AG	A: 9-384	Holoenzyme Co(II) distorted five-coordinated	
3ISQ	2009-09-15	<i>H. sapiens</i> <i>E. coli</i>	A: 9-384	Holoenzyme Co(II) distorted five-coordinated	

1						
2						
3			A:			
4						
5			36-248, 257-431			
6						
7	1SP8		B:			
8						
9	2004-09-21	<i>Z. mais</i>	34-248, 256-432	Holoenzyme		
10				Fe(II)		
11	2.0 Å	<i>E. coli</i> BL21(DE3)	C:			
12				octahedral		
13	24		37-247, 257-431			
14						
15			D:			
16						
17			34-248, 255-432			
18						
19			A:			
20						
21			33-106, 117-193, 202-			
22			210, 216-251, 263-	Holoenzyme		
23	1SP9			Fe		
24			428			
25	2004-09-21	<i>A. thaliana</i>				
26						
27	3.0 Å	<i>E. coli</i>	B:	(iron binding site		
28				not resolved at 3.0 Å)		
29	24		33-106, 117-193, 202-			
30			210, 216-254, 263-			
31						
32			437			
33						
34						
35						
36						
37						
38						
39						
40						
41						
42						
43						
44						
45						
46						
47						
48						
49						




1						
2						
3						
4						
5	1SQD		A:			
6						
7	2004-08-17	<i>A. thaliana</i>	14-173, 180-233, 242-			
8						
9	1.8 Å	<i>E. coli</i> BL21(DE3)	266, 270-382, 390-			
10						
11	23		410			
12						
13						
14						
15						
16						
17						
18						
19			A:			
20			8-212, 224-244, 250-			
21	1SQI					
22						
23	2004-08-17	<i>R. norvegicus</i>	366			
24						
25	2.15 Å	<i>E. coli</i> BL21(DE3)		B:		
26						
27	23		7-210, 224-244, 250-			
28						
29			366			
30						
31						
32						
33						
34						
35						
36						
37						
38						
39						
40						
41						
42						
43						
44						
45						
46						
47						
48						
49						



3

Fe or Co

octahedral



[1TFZ](#)

2004-08-17

A. thaliana

1.8 Å

E. coli BL21(DE3)


23

A:

15-172, 180-230, 242-


266, 270-381, 391-

408



Fe or Co

octahedral

[1TG5](#)

2004-08-17

A. thaliana

1.9 Å

E. coli BL21(DE3)


23

A:

14-173, 179-230, 241-


267, 270-380, 390-


410



Fe or Co

octahedral



			A:		
			4-356		
	1CJX		B:	Acetate	
	2000-04-26	<i>P. fluorescens</i>	4-356	Fe(III)	
	2.4 Å	<i>P. fluorescens</i>	C:	distorted tetrahedral	
	26		4-356		
			D:		
			4-356		

^aAll the structures have been obtained by X-ray diffraction.

^bHPPD chains (A, B, C, and D) and their solved sequence (i.e., the amino acid sequence listed in the PDB structure) are reported.

^cGraphical representations of the binding mode of iron ions, coordinated water, and inhibitors within the HPPD binding site. Pictures have been elaborated with Discovery Studio 3.0 Visualizer software (Accelrys Software, Inc.) by the corresponding PDB files.

^dYang, W. C.; Yang, G. F. Structural insight into the catalytic mechanism of human 4-hydroxyphenylpyruvate dioxygenase. Unpublished results.

^ePilka, E. S.; Shafqat, N.; Cocking, R.; Bray, J. E.; Krojer, T.; Pike, A. C. W.; von Delft, F.; Yue, W. W.; Arrowsmith, C. H.; Weigelt, J.; Edwards, A.; Bountra, C.; Oppermann, U.; Kavanagh, K. L. Crystal structure of human 4-hydroxyphenylpyruvate dioxygenase. Unpublished results.

^fYang, W. C.; Yang, G. F. Crystal structure of *Arabidopsis thaliana* HPPD complexed with NTBC. Unpublished results.

1
2
3 ^sYang, W. C.; Yang, G. F. Crystal structure of *Arabidopsis thaliana* HPPD complexed with sulcotrione. Unpublished results.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1. Reviewed sequences of HPPD stored within the UniProt Knowledgebase (alphabetical order)

UniProt identifier	Organism's scientific name
P93836	<i>Arabidopsis thaliana</i>
Q5EA20	<i>Bos taurus</i>
Q60Y65	<i>Caenorhabditis briggsae</i>
Q22633	<i>Caenorhabditis elegans</i>
Q1E803	<i>Coccidioides immitis</i> (strain RS)
P0CW94	<i>Coccidioides posadasii</i> (strain C735)
E9CWP5	<i>Coccidioides posadasii</i> (strain RMSCC 757)
Q6TGZ5	<i>Danio rerio</i>
O23920	<i>Daucus carota</i>
Q76NV5	<i>Dictyostelium discoideum</i>
P32754	<i>Homo sapiens</i>
O48604	<i>Hordeum vulgare</i>
P69053	<i>Legionella pneumophila</i> (strain Corby)
Q5ZT84	<i>Legionella pneumophila</i> subsp. <i>pneumophila</i> (strain Philadelphia 1, ATCC 33152)
Q96X22	<i>Magnaporthe oryzae</i> (strain 70-15, ATCC MYA-4617)
P49429	<i>Mus musculus</i>
Q872T7	<i>Neurospora crassa</i> (strain ATCC 24698)
Q9ARF9	<i>Plectranthus scutellarioides</i>
Q9I576	<i>Pseudomonas aeruginosa</i> (strain ATCC 15692)

1		
2		
3	P80064	<i>Pseudomonas fluorescens</i> (strain P.J. 874)
4		
5	P32755	<i>Rattus norvegicus</i>
6		
7		
8	Q53586	<i>Streptomyces avermitilis</i> (strain ATCC 31267)
9		
10	Q9S2F4	<i>Streptomyces coelicolor</i> (strain ATCC BAA-471)
11		
12		
13	Q02110	<i>Sus scrofa</i>
14		
15	Q27203	<i>Tetrahymena thermophila</i>
16		
17	Q5BKL0	<i>Xenopus tropicalis</i>
18		
19		
20	Q6CDR5	<i>Yarrowia lipolytica</i> (strain CLIB 122)
21		
22	O42764	<i>Zymoseptoria tritici</i>
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		




Figure 1.






Figure 2.



26
27
28
29
30
31

Figure 3.



53
54
55
56
57
58
59
60

Figure 4.




Figure 5.





Figure 6.

**Figure 7.**




Figure 8.




Figure 9.




Figure 10.




Figure 11.




Figure 12.





Figure 13.



20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 14.




Figure 15.





Figure 16.



12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 17.




Figure 18.






Figure 19.




Figure 20.





Figure 21.



1) first series of pyrazolo-quinazolones
methylated at the C3 of the pyrazole:
R = *o*-F or *o*-Cl, R¹ = Me; best K_i ≈ 80 nM
2) second generation pyrazolo-quinazolones
unsubstituted at the C3 of the pyrazole:
R = *m*-halogen, or *m*-Me, or *m*-OMe
K_i from 10 to 34 nM

pyrazolo-benzimidazoles
R = Me, Et, or Pr
R¹ = Et, Pr, or *i*Pr
K_i from 21 to 77 nM

Figure 22.







Figure 23.



2-benzoyl-1-ethen-1-ol:
the minimum common
pharmacophore



Figure 24.



52: $IC_{50} = 480$ nM

Figure 25.

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



20
21
22
23
24
25

Figure 26.




Figure 27.

Figure captions

Figure 1. Schematic representation of the Phe/Tyr catabolic pathway.

Figure 2. Schematic representation of the chemical structure of the pyrazole derivatives **3** and **4**.

Figure 3. Superposition of the complexes between HPPD (from *Rattus norvegicus*, green sticks, PDB entry 1SQI, and from *Arabidopsis thaliana*, red sticks, PDB entry 1TFZ) and the pyrazole inhibitor **3** (ball and stick notation). Amino acids of the binding site are all conserved and well superposed. Although a 29% amino acid identity, the root mean square deviation on 308 C α atoms of the overall sequence is 1.2 Å. Two of the carbonyl moieties of the inhibitor are part of the coordination sphere of iron ion, together with the three catalytic residues (His and Glu). An aromatic cage of Phe residues accommodates the biphenyl moiety of the inhibitor. The *N*1-*t*Bu substituent is involved in hydrophobic interactions, while no hydrogen bonds are found between the ligand and HPPD. Picture was elaborated with Discovery Studio 3.0 Visualizer software, showing only a few amino acids of the binding site.

Figure 4. Superposition of the complexes between *At*HPPD and the pyrazole inhibitor **3** (green, PDB entry 1TFZ) or **4** (red, PDB entry 1TG5). The root mean square deviation on 362 C α atoms of the overall sequence is 0.3 Å. The sole Phe403 undergoes a 115 degree rotation in the complex with **4**. Iron is coordinated by the usual carbonyl groups of the inhibitor and by the three amino acids of the binding site (His and Glu). Both the phenyl rings of the inhibitor interact by π - π stacking with Phe residues. Picture was elaborated with Discovery Studio 3.0 Visualizer software, showing only a few amino acids of the binding site.

Figure 5. Superposition of the complexes between HPPD (from *Arabidopsis thaliana*, green sticks, PDB entry 5CTO, and from *Streptomyces avermitilis*, red sticks, PDB entry 1T47) and the triketone inhibitor **14** (ball and stick notation). Residues of the binding site are all conserved and

1
2
3 superposed. The root mean square deviation on 314 C α atoms of the overall sequence is 1.4 Å.
4
5
6 The typical interactions between the keto-enol system, the iron ion, and the binding site amino
7
8 acids were found. In addition to π - π stacking with Phe residues, a possible nitro- π stacking was
9
10 also highlighted with Phe336 (1T47). Hydrophobic contacts involved the CF₃ group of the
11
12 inhibitor. Picture was elaborated with Discovery Studio 3.0 Visualizer software, showing only a
13
14 few amino acids of the binding site.
15
16

17
18 **Figure 6.** Proposed mechanism of the HPPD-catalyzed conversion of HPP (**1**) to HGA (**2**).
19
20 Adapted from ref. 34 and 35.
21

22
23 **Figure 7.** Proposed mechanism of the HPPD-catalyzed production of small molecules alternative
24
25 to **2**. Adapted from ref. 34 and 35.
26

27
28 **Figure 8.** Fate of **2** in plants.
29

30
31 **Figure 9.** Fate of **2** in patients with HGD disfunctions.
32

33
34 **Figure 10.** Structure of the most representative HPPD inhibitors belonging to the pyrazole and
35
36 triketone classes.
37

38
39 **Figure 11.** Compound **23** and its active and inactive metabolites.
40

41
42 **Figure 12.** HPPD inhibitors from natural sources: **26** and its congeners.
43

44
45 **Figure 13.** Compound **29** and one by-product of its synthesis (benzoyl dimedone, **30**).
46

47
48 **Figure 14.** Summary of the major structure-activity relationships for triketone
49
50 (cyclohexanedione) HPPD inhibitors.
51

52
53 **Figure 15.** Possible intramolecular cyclization from triketone to dihydroxanthone.
54

55
56 **Figure 16.** Keto-enol tautomerization of a representative triketone compound (**14**).
57

58
59 **Figure 17.** Importance of the triketone system for activity.
60

Figure 18. Benzoyl dimedone derivatives assayed in human fibroblasts.

1
2
3 **Figure 19.** Hybrid compounds by rational design.

4
5 **Figure 20.** Triketones bearing a quinazolindione, a quinoline, or a phenoxyethyl moiety as
6
7
8 HPPD inhibitors.

9
10 **Figure 21.** Summary of the major structure-activity relationships for pyrazole HPPD inhibitors.

11
12 **Figure 22.** Pyrazolo-quinazolones and pyrazolo-benzimidazolones as HPPD inhibitors.

13
14 **Figure 23.** Rational design leading to isoxazole derivatives.

15
16
17 **Figure 24.** Hypothesis on the minimum common pharmacophore derived from representative
18
19
20 examples of isoxazole, triketone, pyrazole, and resorcinol HPPD inhibitors.

21
22 **Figure 25.** Benzoyl-benzothiazines as HPPD inhibitors.

23
24 **Figure 26.** Additional HPPD inhibitors from natural sources.

25
26
27 **Figure 27.** HPPD inhibitors that mimic the substrate (hydrated derivatives of phenylpyruvic acid)
28
29
30 or able to serve as cation chelators.

31
32 **Figure 28.** Metabolic production of toxic compounds due to FAH disfunctions in T1T patients.

33
34 **Figure 29.** A plant-derived syncarpic acid derivative with antiplasmodial activity.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table of Contents graphic

